Skip to main content

Author: Krista Lamb

Le rapport de l’atelier annuel d’Action diabète Canada est maintenant disponible!

[siteorigin_widget class=”MSP_Main_Widget”][/siteorigin_widget]

Les 31 mai et 1er juin 2019, les membres d’Action diabète Canada se sont rassemblés dans le cadre de son quatrième atelier annuel. Après trois années d’activité complètes, nous avons souligné nos nombreuses réalisations, présentées par des patients partenaires, des chercheurs, des stagiaires, des médecins et des partenaires.

De l’avis général, l’atelier annuel 2019 d’Action diabète Canada a été le plus réussi jusqu’à présent!  Nous étions ravis de pouvoir rassembler les membres de notre équipe, qui exerce ses activités d’un océan à l’autre. Cela leur a donné l’occasion d’établir des liens, de solidifier leur réseau et d’apprendre les uns des autres. En tout, nous avons accueilli 112 participants, dont 29 patients partenaires, 41 chercheurs et 8 invités, notamment Tia Moffat, chef de projet, Initiatives principales IRSC-SRAP, ainsi que Norm Rosenblum et Mary-Jo Makarachuk, respectivement directeur et directrice adjointe de l’Institut de la nutrition, du métabolisme et du diabète des IRSC.

Cette année, nous avons présenté nos résultats de recherche de façon tangible dans le cadre de diverses activités, y compris une séance interactive d’affiches, de brefs exposés oraux, des séances plénières, des séances en atelier et un discours liminaire. Toutes ces activités étaient adaptées à notre auditoire diversifié composé de patients partenaires, de décideurs, de leaders des IRSC, de chercheurs et d’utilisateurs des connaissances de nombreuses disciplines. Cette année, nous avons également eu l’honneur d’entendre nos patients partenaires nous expliquer ce que vivre avec le diabète signifie et leur rôle de conseiller dans les projets de recherche. Cette tribune donnée aux patients nous a vivement rappelé pourquoi Action diabète Canada est si motivé à produire des résultats de recherche qui serviront aux personnes qui vivent avec le diabète. Les commentaires reçus à propos de notre atelier ont été très positifs et de nombreux participants ont applaudi la diversité des activités, la possibilité de participer à des séances en atelier ainsi que les témoignages des patients partenaires.

Vous trouverez ci-dessous un compte rendu détaillé de l’événement.

[siteorigin_widget class=”SiteOrigin_Widget_Button_Widget”][/siteorigin_widget]

Diabetes Canada Professionals Conference Halifax 2018 – Scientific Ambassadors Final Report Now Available

In October 2018, Diabetes Canada held its annual professional conference in Halifax, NS.  Diabetes Action Canada supported two Patient Partners, Doug Mumford and Robert Fenton, as Scientific Ambassadors, to attend the Diabetes Canada Conference and participate in sessions of interest.  We are pleased to now have a full report on their experiences at the conference.  Please see below for both an English and French version of this report.

In summary the Scientific Ambassadors took away from the conference:

  1. Treat the mind as well as the body. Necessity of treating the mind as well as the body.  And of measuring the mind – especially the willingness for the patient to change their behavior in favor of self-management.
  2. Assess the patients’ willingness to change their behavior before offering a treatment plan.
  3. Follow up with each patient – clinicians and educators need to monitor compliance and results.
  4. Data is an absolute key to success in diabetes management at the personal as well as the population level.
  5. True patient-centered care is vital. Lots of talk about Shared Decision Making (SDM) with the patient, and about the necessity to follow up after initial visits.  This especially applied to people living with Type 2 who tend to be seen only a few times by an education centre and endocrinologist, then the family doctor is expected to continue from there.  It doesn’t work that well.
  6. A1c is on the way to being replaced by two numbers:  Time in Target, and Time in Hypo.  Like ≥75% and ≤3%.
  7. New developments in glucose monitoring and insulin delivery systems are making diabetes management easier and more effective.
  8. Obesity is not curable, and current best treatment practices are not scalable (bariatric surgery and cognitive behavior modification).
  9. Prevention and early treatment of complications is crucial.
  10. Clinical Practice Guidelines 2018 have been updated to an “app” as well as a website, and are an outstanding tool for clinicians, educators, and patients.
  11. Inspiration: There are no limits to what people with diabetes can be, do, or accomplish!

 

[siteorigin_widget class=”SiteOrigin_Widget_Button_Widget”][/siteorigin_widget]
[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

Scientific Ambassador, Doug Mumford next to the National Diabetes Repository Poster presented at the 2018 Diabetes Canada Professional Conference in Halifax, NS

Diabetes Action Canada Annual Workshop Report now Available!

[siteorigin_widget class=”MSP_Main_Widget”][/siteorigin_widget]

On May 31st- June 1st, 2019, member of Diabetes Action Canada came together for its fourth Annual Workshop. After three full years in operation, we highlighted our many accomplishments – presented by Patient Partners, Investigators, Trainees, Clinicians and Partners.

By all accounts, our 2019 Diabetes Action Canada Annual Workshop, was the most successful yet!  We were thrilled to bring our team that spans the nation, together in person to connect, network, and learn from each other.  In total we had 112 participants at our event, including 29 Patient Partners, 41 Investigators and 8 guests, including Tia Moffat, Project Lead CIHR-SPOR Major Initiatives, Norm Rosenblum, Director, and Mary-Jo Makarachuk, Assistant Director of the CIHR Institute for Nutrition, Metabolism and Diabetes.

This year we presented our tangible research outcomes in a variety of activities including, interactive poster session, rapid-fire oral presentations, plenary sessions, breakout sessions, and keynote address.   All these activities were tailors to our diverse audience of Patient Partners, Policy Decision-Makers, CIHR leaders, investigators and knowledge users from many disciplines.  This year, we were also honoured to hear the stories of our Patient Partners and their experiences living with diabetes and advising on research projects.  This patient narrative was a compelling reminder of the why Diabetes Action Canada is so motivated to create research outcomes that are applicable to those living with diabetes.  The feedback we received from our Workshop was very positive with comments lauding the diversity of activities, the opportunities to participate in break-out sessions, and the inclusion of Patient Partner stories.

A full account of the event can be found below.

*French version is forthcoming*

[siteorigin_widget class=”SiteOrigin_Widget_Button_Widget”][/siteorigin_widget]

Série d’apprentissage estival 2019 du réseau BRILLEnfant

[siteorigin_widget class=”SiteOrigin_Widget_Hero_Widget”][/siteorigin_widget]

Le réseau BRILLEnfant est ravi de vous annoncer que l’inscription à notre Série d’apprentissage estival 2019 (SAE) est ouverte! La SAE est une occasion pour les participants de se rassembler virtuellement et d’approfondir différents sujets liés à la recherche axée sur le patient.

Cette année, nous organiserons 4 webinaires gratuits et ouverts aux membres des différentes réseaux SRAP / Unités de SOUTIEN et au grand public. Vous pouvez en savoir plus sur chaque session et vous inscrire en utilisant les liens fournis ci-dessous :

Horaire de la Série d’apprentissage estival 2019 du réseau BRILLEnfant :

Le 11 juin
Trust and Teamwork: Best Practices for Collaborative Research

Le 27 juin
Enhancing Participation in Research

Le 17 juillet
Reciprocity: A Framework for Families and Researchers to Move on a Two-Way Street

Le 22 août
Supporting First Nation-Centred Research & Meaningful Collaboration

Les places sont limitées, alors réservez la vôtre dès aujourd’hui!

Nous attendons avec impatience votre participation et votre contribution à ces discussions importantes. Pour toutes questions ou commentaires, n’hésitez pas à nous contacter à pierre.zwiegers@child-bright.ca.

CHILD-BRIGHT’s 2019 Summer Learning Series

[siteorigin_widget class=”SiteOrigin_Widget_Hero_Widget”][/siteorigin_widget]

CHILD-BRIGHT is thrilled to announce that registration for our 2019 Summer Learning Series (SLS) is now open! The SLS is an opportunity for participants to virtually gather and delve deeper into different topics related to patient-oriented research.

This year we will be hosting 4 webinars that are free and open to members of various SPOR Networks / SUPPORT Units and the general public. Learn more about each session and register using the links provided below:

CHILD-BRIGHT’s 2019 Summer Learning Series Schedule:
June 11
Trust and Teamwork: Best Practices for Collaborative Research

June 27
Enhancing Participation in Research

July 17
Reciprocity: A Framework for Families and Researchers to Move on a Two-Way Street

August 22
Supporting First Nation-Centred Research & Meaningful Collaboration
Spaces are limited, so reserve your spot today!

We look forward to your participation and contribution to these important discussions. For any questions or comments, please feel free to contact us at pierre.zwiegers@child-bright.ca

Tidepool working with diabetes device manufacturers to empower the diabetes community with their health data

If you attended the American Diabetes Association (ADA) 2019 Scientific Sessions, you might have heard first-hand the news that Tidepool is working with diabetes device manufacturers Metronic, Dexcom, and Omnipod to help create an interoperable automated insulin pump system – Tidepool Loop.  Tidepool is a non-profit data hub for patients and clinicians to combine and view data for insulin pumps, CGMs and blood glucose and make it easy to understand and interpret.   Medtronic manufactures the only commercial available hybrid closed-loop system (aka artificial pancreas) and its components CGM and insulin pump.  Dexcom manufactures the G6 interoperable continuous glucose monitoring system (iCGM), and the Omnipod System that is a wearable three day insulin delivery system.   Together these manufacturers plan to work with Tidepool on the regulatory and software processes necessary to develop Tidepool Loop as an FDA–regulated version of Loop.

This is big news to those using or wishing to use a hybrid closed loop system as these developments open the door to interoperability of devices that will empower people with diabetes in their health care decision-making.  Although this technology is planned to be launched in the USA, Diabetes Action Canada currently has two funded clinical studies testing an artificial pancreas algorithm.  The first study led by Dr. Bruce Perkins will identify the feasibility and efficacy of combined SGLT2 inhibition therapy and artificial pancreas treatment using quantitative outcome measures and questionnaires in subjects with type 1 diabetes.  The second led by Dr. Remi Rhabasa-Lhoret, examines an insulin pump technology that includes two configurations, one that infuses insulin (single-hormone) alone and another that infuses insulin and the counter-regulatory hormone glucagon (dual-hormone).  We are also working with Tidepool to integrate the system into our digital assets. We expect that this technology will soon be available to Canadians and informed by Canadians and our health system.

News release on Medtronic and Tidepool collaboration can be found here

News release on Dexcom and Tidepool collaboration can be found here

News release on Omnipod and Tidepool collaboration can be found here

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

New study on Teplizumab delays onset of type-1 diabetes for at-risk individuals

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

The cause of type-1 diabetes is still unknown with many factors at play but none conclusive. Scientists have however learned that type 1 diabetes begins years before it is diagnosed when a person’s own immune system launches subtle attacks on the beta cells in the pancreas. In a recent study, Herold et al. 2019, discovered that the an anti-CD3 antibody, Teplizumab, originally intended to protect new organs after kidney transplantation, could deactivate T cells that are targeting insulin producing beta cells.   This study investigated people who were at high risk of developing type-1 diabetes (have a first degree relative with type-1) but had not yet been diagnosed.  Using a double-blind randomized method, participants were assigned a single 14-day course of Teplizumab or placebo and follow-up tests for progression to type-1 diabetes were performed at 6-month intervals.  The results showed that a single dose of Teplizumab delayed progression of type-1 diabetes by approximately two years in those at risk of developing type-1 diabetes.   This is a ground-breaking study as previously there was no tangible method of preventing, or in this case delaying, type-1 diabetes for high risk individuals.   Further investigation of Teplizumab will raise an interesting ethical debate as the findings from this study have proven delayed onset of Type-1 diabetes, and therefore trial design using placebo might be denying participants, particularly children age 12 and below, the opportunity for a delay in a type-1 diabetes clinical diagnosis.

The full research article published in the New England Journal of Medicine can be found here

Type 1, Type 2, Type 1.5, LADA, or MODY?

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]
Part A

Determining what kind of diabetes someone has is not always easy in the adult population. It is becoming clear that T1D is not simply a pediatric disease or a disease of early adulthood – a genetic, population-based UK study suggests that genetically-defined type 1 diabetes between 30 and 60 years of life is a distinct condition with a different clinical course than type 2 diabetes, with lower BMI and more rapid progression to insulin dependence [1]. When defined this way T1D diagnosed after age 30 represents approximately 40% of all cases of T1D but only 4% of all cases of diabetes diagnosed after age 30.  The diagnosis of T1D in people over 30 is obscured by the massive increase in the prevalence of T2D after the age of 30, explaining why it is so easy to misdiagnose T1D in which the onset of diabetes occurs after age 30.

Because genetic testing is not currently performed in patients we typically see in our clinical practice, can we utilize simple and readily available biomarkers such as plasma C-peptide to diagnose T1D in adults, defined by severe endogenous insulin deficiency after age 30 progressing to rapid insulin requirement within 3 years of diagnosis?  A recently published study suggests that transition to insulin requirement within 3 years of diagnosis and very low C-peptide levels (< 200pmol/l or 0.2 nmol/l) identifies individuals who have similar clinical and biological characteristics (such as high islet autoantibody prevalence) to that occurring at younger ages, but is frequently not identified as having T1D[2].  The importance of identifying these patients who demonstrate rapid progression to pancreatic beta cell failure is that they are profoundly insulin deficient and therefore insulin dependent and consequently ketosis prone and are best labelled as having T1D.

Part B

The University of Exeter group has developed an app which can help predict the likelihood of T1, T2 or MODY.

iOS Diabetes Diagnostics* on the App Store – iTunes – Apple

Android Diabetes Diagnostics* – Apps on Google Play

*The Diabetes Diagnostics app is a clinical aid for the differential diagnosis of diabetes subtypes. The app combines information from national and international diabetes guidelines, the MODY clinical prediction calculator, and expert opinion from world leaders in monogenic diabetes to provide a resource to help guide diabetes classification.


[1] Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. The Lancet Diabetes & Endocrinology. 2017 Nov 30;6(2):122–9

[2] Thomas NJ, Lynam AL, Hill AV, Weedon MN, Shields BM, Oram RA, McDonald TJ, Hattersley AT, Jones AG. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes.  Diabetologia. 2019 Apr 10: 1-6

A Diabetes Strategy For Canada – Recent report of the House of Commons Standing Committee on Health

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

The Standing Committee on Health (all Party) for the Canadian House of Commons has just released its report, A Diabetes Strategy For Canada. Over the course of six meetings held in the spring and fall of 2018, the Committee heard from 32 witnesses and received 12 briefs.  Of these meeting Diabetes Action Canada alongside patient advocacy groups (Diabetes Canada, JDRF, Canadian Indigenous Nursing Association), health care providers, and people living with diabetes, discussed the current health care issues experiences by those living with diabetes and presented staggering evidence to support a coordinated and overarching framework to improve diabetes management and patient experiences.  Minutes from the meetings attended by Diabetes Action Canada can be found here and here.

 

The report released by Committee includes a list of recommendations to the Government of Canada, to enable better prevention of type-2 diabetes and more support to all people living with diabetes. Of the eleven recommendations, several are particularly relevant to the mission of Diabetes Action Canada and the research projects underway.  Below is a brief summary of these recommendations to inform our future direction as we look to the next phase of our Network:

 Recommendation 1:

The Government of Canada, in partnership with the provinces and territories, and in collaboration with stakeholders such as Diabetes Canada, plan and implement an approach to the prevention and management of diabetes in Canada through a national diabetes strategy, as outlined in Diabetes Canada’s Diabetes 360°: A Framework for a Diabetes Strategy for Canada. The partnership should facilitate the creation of Indigenous-specific strategic approaches led and owned by any Indigenous groups wishing to embrace this framework.

Recommendation 2:

As part of the national diabetes strategy, the Government of Canada, in partnership with the provinces and territories, and in collaboration with stakeholders such as Diabetes Canada:

  • explore options for establishing a national diabetes registry for people living with both type 1 and type 2 diabetes;
  • explore options to reduce diabetes-related stigma; and
  • explore options to improve public awareness and education on diabetes, particularly through community programming, including public awareness of the relationship between nutrition and diabetes.

Recommendation 3:

That the Government of Canada provide funding through the Canadian Institutes of Health Research for research into preventing and treating type 1 and type 2 diabetes

Recommendation 9:

The Government of Canada hold discussions with the provinces and territories to explore possible approaches to improving access to health care for individuals living with diabetes in rural, remote and northern communities.

To access the full report by the Committee please visit here.  To learn more about the activities of the Standing Committee on Health please visit their site here.

Adjunct Therapies in Type 1 Diabetes

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

To date there are no licensed therapies for Type 1 diabetes except insulin in Canada. Recently the European Medicines Agency has given approval for Dapaglifozin in T1D, while the FDA rejected Sotagliflozin. Trials of these agents in Type 1 have shown modest reductions in HbA1c, weight and insulin use, with an increase in Time in Range. These benefits were at the expense of a increase in risk of DKA-despite the clinical trial setting – where oversight is much stricter than in routine clinical practice.  Safe use of these agents in type 1 will require substantial education for prescribers and most importantly, patients. Helping people think about taking insulin to treat elevated ketone levels and not just if blood glucose levels are high is a major paradigm shift. Enabling safe use seems a more patient focused approach than prohibiting access to therapies which may have significant benefits for sane individuals with type one diabetes. The potential benefit of combining these agents with artificial pancreas is currently being investigated in a Diabetes Action Canada study led by Dr. Bruce Perkins

Diabetes Action Canada has a new look!

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

After months of hard work, stakeholder consultations and training, we are thrilled to announce the launch of our brand new bilingual website!  The new site has the same URL as the previous site and can be found at http://s971398767.online-home.ca/.

Our goal with this new interactive website is to provide our Researchers, Patient Partners, Stakeholders, and anyone interested in user-friendly navigation to learn about Diabetes Action Canada research programs, activities and initiatives.   Information on each of our research programs is profiled directly on our homepage and detailed information is only one click away!

Amongst the new features, the site contains direct access to the National Diabetes Repository site https://repository.diabetesaction.ca/, designed to enable a user-friendly platform to request access to our multi-province diabetes data for the purposes of secondary research.

We will be constantly updating our content with helpful information, articles, news, newsletters, announcements and patient stories.

We hope you that find the new website, with a fresh look, easy to access information and we welcome comments and feedback on the new design.

Vigorous Interval Exercise and its Effect on Hypoglycemia in Type-1 Diabetes

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

Hypoglycemia is the most life-threatening complication faced by persons with type-1 diabetes (T1D) and is exacerbated by physical activity. This risk often deters individuals with T1D from engaging in active lifestyles. In a recent study by Dr. Jonathan McGavock and colleagues published in Nature Scientific Results, the effects of adding vigorous intensity intervals to moderate intensity endurance exercise on blood glucose in persons with T1D was examined. This multi-centre, single-blinded, 16-week randomized control trial examined the effect on hypoglycemia in two groups: those engaged in moderate intensity physical activity alone, and those engaged in moderate intensity physical activity plus intermittent vigorous intensity exercise. The study found that persons who were previously inactive, aged 15-45 years, who added vigorous intensity intervals to moderate-intensity exercise program (16-week) intervention did not reduced the risk of post-exercise hypoglycemia. This was a surprising result as previous studies suggested that vigorous intensity interval training stabilized blood glucose following moderate intensity endurance exercise or prevented exercise-related nocturnal hypoglycemia in individuals with T1D. To read the full article follow this link

Continue reading

Supporting diabetes patients with complex conditions (Ontario SPOR SUPPORT Unit Newsletter)

How is diabetes managed in the frail elderly? Read how OSSU, Better Access and Care for Complex Needs (BeACCoN) and Diabetes Action Canada address these complex health conditions in a complex health system, a first-of-its-kind collaboration. The full story can be seen in OSSU’s newsletter. Click Here to read  full story

 

Diabetes Action Canada will like to congratulate  Dr. Michelle Greiver on being awarded a $2.6 million competitive operating grant. The grant will fund a SPIDER (Structured Process Informed by Data, Evidence and Research) approach, supporting primary care practices in optimizing care for patients with complex needs.

CLick here to read the full article published by  Canadian Health Care Technology

Dépistage de la rétinopathie diabétique

Dépistage de la rétinopathie diabétique

Responsables


Chercheurs associés : Marie Carole Boucher, Melanie Campbell, Varun Chaudhary, Alan Cruess, Sherif El Defrawy, Mahyar Etminan, Bernard Hurley, Stephen Kosar, Jason Noble, Chris Rudnisky, Tom Sheidow, David Wong

Objectifs

Prévenir la cécité grâce au programme de dépistage rétinien à distance

Déterminer le rapport coût-efficacité associé au programme de dépistage rétinien à distance

Consulter les personnes diabétiques pour comprendre, selon le point de vue des populations vulnérables, les facteurs qui freinent ou facilitent l’accès au dépistage de la rétinopathie diabétique

Répertorier et faire participer les personnes qui sont à risque de développer une rétinopathie diabétique pour entamer le dépistage préventif

Utiliser l’intelligence artificielle et l’apprentissage machine (lecture automatique des images de la rétine) pour détecter la rétinopathie diabétique et d’autres maladies des yeux

Les personnes diabétiques sont plus à risque d’être aux prises avec un trouble de la vision. L’excès chronique de sucre dans le sang peut endommager le fond de l’œil (rétine), entraînant une enflure, des saignements et des cicatrices; il peut en résulter un trouble de la vision, voire une perte de la vue. Maladie qui peut rendre aveugle, la rétinopathie diabétique est une complication grave du diabète et constitue la principale cause de cécité chez les adultes de moins de 65 ans (en âge de travailler). Au stade précoce, la maladie ne présente aucun symptôme, mais elle peut rapidement évoluer aux stades avancés. Si elle n’est pas traitée, elle peut entraîner une grave perte de la vision et même la cécité.

Prévenir la cécité grâce au programme de dépistage rétinien à distance

Diabète Canada recommande à toutes les personnes diabétiques de se soumettre à un examen de la vue spécial chez un ophtalmologue ou un optométriste tous les ans ou tous les deux ans. Malgré cette recommandation, seulement 60 % des personnes diabétiques subissent régulièrement un examen de la vue. Pour cette raison, des milliers de Canadiens sont aux prises avec un trouble de la vision, l’une des complications du diabète parmi les plus redoutées.

La détection précoce de la rétinopathie diabétique, par un dépistage régulier de la rétine, est une méthode efficace pour prévenir la perte de la vision causée par le diabète. Il existe des traitements efficaces qui sont en mesure de prévenir la perte de la vision et de ralentir la progression des dommages s’ils sont détectés précocement. C’est pour cette raison qu’il est essentiel de soumettre toutes les personnes diabétiques à un examen de dépistage afin de détecter la présence de la rétinopathie diabétique à un stade précoce ou avancé.

Les jeunes adultes atteints du diabète de type 1, les Autochtones, les nouveaux immigrants et les personnes vivant dans les quartiers défavorisés des centres-villes et dans les collectivités éloignées affichent des taux de dépistage parmi les plus faibles. Malheureusement, nous savons que de nombreuses personnes diabétiques n’ont pas accès à des examens de la vue de manière régulière. Or, ces personnes ont la possibilité de subir un examen de la vue au moyen d’un système d’imagerie mobile (télémédecine), à savoir le programme de dépistage rétinien à distance. Les images de la rétine sont téléversées sur un serveur qui permet aux spécialistes de la rétine d’y accéder à distance. Ils peuvent ainsi évaluer l’état d’avancement de la rétinopathie, puis transmettre au fournisseur de soins primaires des recommandations relatives à la prise en charge de la maladie. À l’heure actuelle, plus de 500 sites offrent des services de dépistage de la rétinopathie diabétique à distance dans les quartiers défavorisés des centres-villes et dans les collectivités éloignées de l’Ontario, du Québec, de la Colombie-Britannique, de l’Alberta et du Manitoba; la majorité d’entre eux étant situés dans l’Ouest canadien. Toutefois, les programmes provinciaux n’étant pas uniformes, l’accessibilité au dépistage rétinien continue de poser problème.

Action diabète Canada s’efforce d’élaborer un programme national pour le dépistage rétinopathie diabétique qui visera à : prévenir les troubles de la vision et la cécité causés par le diabète; et éliminer les facteurs qui empêchent tous les Canadiens diabétiques d’avoir accès au service de dépistage. Notre groupe procède à la mise en œuvre d’une approche axée sur les pratiques exemplaires pour le diagnostic précoce et la prise en charge de la rétinopathie diabétique qui a de fortes chances d’être appliquée à grande échelle dans d’autres régions.

En Ontario, en partenariat avec Ontario Telehealth Network (OTN), Action diabète Canada envisage de collaborer avec chacun des réseaux locaux d’intégration des services de santé (RLISS) à la mise au point d’un programme personnalisé et durable qui pourra être intégré aux programmes régionaux de prise en charge des maladies chroniques déjà existants par l’entremise des centres de santé communautaires (CSC), des équipes de santé familiale, des programmes d’éducation sur le diabète et d’autres services. Le Dr Michael Brent, directeur national de notre groupe de travail sur le dépistage de la rétinopathie diabétique, a mis sur pied un programme de dépistage en collaboration avec des technologues experts dans les quartiers défavorisés des centres-villes et dans les collectivités éloignées présentant un nombre élevé de personnes diabétiques. Équipé d’un système portatif d’imagerie de la rétine, un technicien se rend d’un site à l’autre, fait subir au patient un examen de la vue pour le dépistage de la rétinopathie diabétique et lui transmet de l’information sur le diabète. Par la suite, les images de la rétine sont téléversées sur un serveur et rapidement évaluées par un ophtalmologue (le spécialiste de la rétine). Les personnes à risque ou qui ont besoin d’une intervention pour traiter une rétinopathie diabétique mettant en péril leur vue sont sans tarder renvoyées vers un spécialiste et prises en charge par les champions de la rétine de chaque RLISS.

Ce groupe a démontré la faisabilité et l’efficacité des mesures visant à diagnostiquer une maladie pouvant rendre aveugle qui était jusqu’alors passée inaperçue. Jugé prioritaire dans tous les RLISS de l’Ontario, ce programme est l’exemple parfait d’un projet qui vise à renforcer l’accès à des soins équitables, tout en illustrant le potentiel d’application à grande échelle du programme dans d’autres provinces et territoires. Par exemple, les responsables du programme de dépistage de la rétinopathie diabétique, dirigé par le Dr Stephen Kosar, en collaboration avec l’équipe de santé familiale du centre de santé de Manitoulin et l’OTN, axent présentement leur étude sur l’ensemble des personnes diabétiques d’origine autochtone vivant sur l’île Manitoulin.

En Colombie-Britannique, le Dr David Maberley, coresponsable de notre groupe de travail sur le dépistage de la rétinopathie, effectue actuellement une évaluation pragmatique de deux nouveaux sites de dépistage. Le premier est situé dans la communauté éloignée de la Première Nation Heiltsuk (Bella Bella); le deuxième, dans l’est du centre-ville de Vancouver. Ces sites serviront de base à l’élaboration d’un programme communautaire efficace pour le dépistage de la rétinopathie diabétique. À l’aide d’un nouveau logiciel pour la saisie de données sur les images de la rétine et la technologie de transfert, le groupe vise à automatiser l’analyse des images de manière à améliorer l’efficacité du programme de même que le triage des patients (à risque faible ou élevé) pour que l’équipe chargée des soins primaires ou spécialisés puisse leur offrir le traitement et le suivi appropriés.

 

Déterminer le rapport coût-efficacité associé au programme de dépistage rétinien à distance

Mme Valeria Rac (Toronto Health Economics and Technology Assessment ou THETA) a utilisé les données recueillies dans le cadre d’un projet pilote réalisé en collaboration avec le Centre de santé communautaire de Riverdale-Sud pour évaluer le rapport coût-efficacité associé au programme de dépistage rétinien à distance. Selon cette évaluation, ce programme, qui repose sur l’utilisation d’une caméra portative pour la prise d’images de la rétine, permet de détecter la rétinopathie diabétique à moindre coût, comparativement à l’examen de la vue courant effectué à des fins de dépistage dans les collectivités (semi)urbaines de Toronto auprès des personnes diabétiques qui sont à risque de développer cette maladie et qui n’ont pas accès aux spécialistes des soins de la vue.

Consulter les personnes diabétiques pour comprendre, selon le point de vue des populations vulnérables, les facteurs qui freinent ou facilitent l’accès au dépistage de la rétinopathie diabétique

En collaboration avec l’Université Laval et l’Institut de recherche de l’Hôpital d’Ottawa, nous avons mis sur pied un nouveau projet de recherche, pour lequel les responsables recrutent activement des participants en ce moment. À l’aide d’entrevues structurelles, l’équipe de projet vise à répertorier et à comprendre les facteurs qui freinent ou facilitent l’accès au dépistage de la rétinopathie diabétique en Ontario et au Québec chez les minorités ethnoculturelles qui courent un risque élevé de développer cette maladie (à savoir les immigrants originaires de l’Asie du Sud ou de la Chine ainsi que les immigrants francophones d’origine africaine). L’équipe de projet se servira des résultats obtenus pour mettre au point des interventions adaptées qui permettront concrètement d’éliminer les difficultés auxquels se heurtent ces groupes.

 

Répertorier et faire participer les personnes qui sont à risque de développer une rétinopathie diabétique pour entamer le dépistage préventif

Diabète Canada recommande à toutes les personnes diabétiques de se soumettre à un examen de la vue spécial chez un ophtalmologue ou un optométriste tous les ans ou tous les deux ans; les personnes présentant un risque élevé devraient, pour leur part, subir un examen plus fréquemment. Selon des données récentes, seulement 60 % des personnes diabétiques subissent un examen de la vue. Pour cette raison, des milliers de Canadiens sont aux prises avec un trouble de la vision. Nous envisageons d’utiliser les bases de données administratives provinciales et le Répertoire national du diabète pour répertorier les personnes diabétiques qui n’ont pas subi d’examen de la vue depuis plus de deux ans. Par la suite, nous avons l’intention d’entrer en contact avec ces personnes par l’entremise de leur centre de santé communautaire ou de leur professionnel en soins primaires afin de les inviter à un centre offrant des services de dépistage rétinien à distance pour les soumettre à un examen de dépistage de la rétinopathie diabétique. En communiquant directement avec ces patients, nous parviendrons à améliorer leurs connaissances au sujet de la rétinopathie diabétique, augmenter les taux de dépistage et prévenir la perte de la vision.

Utiliser l’intelligence artificielle et l’apprentissage machine (lecture automatique des images de la rétine) pour détecter la rétinopathie diabétique et d’autres maladies des yeux

La lecture des images de la rétine exige beaucoup de temps et demeure un processus essentiellement manuel. Au moment de la mise en œuvre à grande échelle du programme de dépistage rétinien à distance, nous serons confrontés à des obstacles majeurs en ce qui concerne le temps de lecture des images par les techniciens et les médecins. Nous espérons faire subir un examen de dépistage à tous les Canadiens qui sont à risque de développer la rétinopathie diabétique; or, la lecture des images sera une contrainte majeure qui risque de ralentir la pose du diagnostic et le début du traitement. Dans le cadre d’une nouvelle initiative stimulante réalisée en collaboration avec un groupe de chercheurs du Département d’ophtalmologie de l’Université de Montréal, de l’École polytechnique de Montréal et de l’Institut des algorithmes d’apprentissage de Montréal (MILA), Action diabète Canada étudie présentement le rôle que joue l’intelligence artificielle dans l’analyse des images de la rétine. Ce groupe de scientifiques procède à la mise au point de nouveaux algorithmes faisant appel à des technologies avancées pour faire la lecture des images du fond de la rétine et des images prises par tomographie par cohérence optique dans le but de poser un diagnostic de rétinopathie diabétique ou d’autres maladies oculaires. L’initiative axée sur l’intelligence artificielle permettra d’améliorer les soins et les résultats pour les personnes diabétiques, tout en facilitant l’accès aux spécialistes des soins de la vue et en augmentant la productivité des cliniciens.

 

Felfeli, R. Alon, R. Merritt et M.H. Brent. « Toronto tele-retinal screening program for the detection of diabetic retinopathy and macular edema in urban and rural settings: a case series », Journal canadien d’ophtalmologie, 2018. Consulté en ligne le 23 août 2018 : https://doi.org/10.1016/j.jcjo.2018.07.004.

Boucher, M. C., G. Desroches, R. Garcia-Salinas, A. Kherani, D. Maberley, S. Olivier et autres. « Teleophthalmology screening for diabetic retinopathy through mobile imaging units within Canada », Journal canadien d’ophtalmologie, 2008, 43(6), p. 658-668.

Hooper, P., M. C. Boucher, A. Cruess, K. G. Dawson, W. Delpero, M. Greve et autres. « Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy », Journal canadien d’ophtalmologie, 2012, 47(2 Suppl):S1-30, S1-54.

Vieillissement, santé communautaire et des populations

vieillissement et la santé communautaire et des population

notre équipe

 

Objectif

Travailler avec les aînés aux prises avec de multiples maladies chroniques et leurs proches aidants en vue de favoriser un vieillissement optimal à la maison

L’Unité de recherche sur la santé, la communauté et le vieillissement (URSCV) a récemment obtenu un financement grâce à une subvention des IRSC : Réseau de la SRAP sur les innovations en soins de santé de première ligne et intégré (ISSPLI) et à Action diabète Canada. Ce financement lui permettra de mener une étude à plusieurs sites intitulée programme de partenariat communautaire de l’URSCV visant à favoriser l’autoprise en charge du diabète chez les aînés canadiens.

Contexte : Adopté par l’Unité de recherche sur la santé, la communauté et le vieillissement (URSCV), le programme de partenariat communautaire est une intervention de six mois qui vise à favoriser l’autoprise en charge du diabète chez les aînés diabétiques qui sont aux prises avec d’autres maladies chroniques et à offrir du soutien à leurs proches aidants (famille ou amis). Il vise à améliorer les résultats associés à l’objectif à quatre visées : 1) la santé des populations; 2) l’expérience des patients et des proches aidants; 3) l’expérience des fournisseurs de soins; et 4) les coûts. Le programme de recherche s’appuie sur les données probantes faisant état de la faisabilité et de l’efficacité du programme de partenariat communautaire de l’URSCV qui ont été recueillies dans le cadre de nos travaux antérieurs. Il a été conçu dans l’optique de le mettre en œuvre à grande l’échelle.

Objectif de l’étude : L’approche consiste en une intervention de six mois qui s’articule autour de plusieurs volets et qui repose sur des données probantes. Elle a pour objectif d’intégrer les soins dans tous les milieux de manière à améliorer la qualité des soins et les résultats en matière de santé pour les aînés diabétiques (65 ans ou plus) qui vivent dans la collectivité et qui sont aux prises avec au moins une autre maladie concomitante, et à offrir du soutien à leurs proches aidants (famille ou amis).

Cette intervention s’articule autour de quatre volets principaux qui mettent à profit l’expertise des fournisseurs de soins de santé œuvrant dans des disciplines différentes. Elle prévoit également la mise en place d’un partenariat entre les organismes communautaires spécialisés en soins primaires :

Coordination des soins et navigation dans le système sous la direction d’une infirmière;

Visites à domicile réalisées par des éducateurs agréés en diabète (infirmières autorisées et diététistes) œuvrant pour les programmes d’éducation sur le diabète en lien avec les soins primaires;

Séances de groupe communautaires mensuelles animées conjointement par un partenaire communautaire (p. ex., YMCA) et un représentant du programme d’éducation sur le diabète associé aux soins primaires;

Conférences de cas mensuelles pour l’équipe d’intervention.

Des études ont démontré que, d’un point de vue statistique, la qualité de vie, notamment la santé mentale, et l’autoprise en charge de la maladie chez les aînés qui bénéficiaient du programme de partenariat communautaire de l’URSCV en Ontario s’étaient considérablement améliorées, en comparaison aux patients qui recevaient les soins habituels pour le diabète. De plus, leurs symptômes de dépression s’étaient mieux résorbés. L’intervention a été bien accueillie par les patients, les aidants et les fournisseurs de services. Qui plus est, les améliorations décrites ont été réalisées sans engendrer de frais supplémentaires pour l’ensemble du système de santé. Enfin, des données préliminaires portent à croire que le programme de l’URSCV, une fois mis en œuvre à grande échelle, procurera des bienfaits et permettra de réaliser des économies.

Des études ont démontré que, d’un point de vue statistique, la qualité de vie, notamment la santé mentale, et l’autoprise en charge de la maladie chez les aînés qui bénéficiaient du programme de partenariat communautaire de l’URSCV en Ontario s’étaient considérablement améliorées, en comparaison aux patients qui recevaient les soins habituels pour le diabète. De plus, leurs symptômes de dépression s’étaient mieux résorbés. L’intervention a été bien accueillie par les patients, les aidants et les fournisseurs de services. Qui plus est, les améliorations décrites ont été réalisées sans engendrer de frais supplémentaires pour l’ensemble du système de santé. Enfin, des données préliminaires portent à croire que le programme de l’URSCV, une fois mis en œuvre à grande échelle, procurera des bienfaits et permettra de réaliser des économies.

Effets sur le système de santé et les patients

Des soins axés sur la personne pour les patients ayant des besoins élevés/faisant grand usage du système de soins

La mise en œuvre de l’intervention auprès des populations diversifiées de l’Ontario, du Québec et de l’Île-du-Prince-Édouard, où les participants sont délibérément choisis parmi certaines des populations les plus vulnérables, permettra de cerner avec exactitude les pratiques exemplaires ou inefficaces et de comprendre les raisons de cette situation. De cette manière, l’équipe de recherche pourra recueillir l’information nécessaire pour restructurer les programmes en place pour la prise en charge du diabète et des maladies chroniques, lesquels doivent être personnalisés pour répondre aux besoins propres à chaque population.

Modèle général relatif à la mise en œuvre à grande échelle des interventions en faveur de l’atteinte de résultats dans toute la province

En plus de produire des données probantes visant à élargir la portée du programme de partenariat communautaire de l’URSCV, le programme permettra de mettre à l’essai un modèle général relatif à la « mise en œuvre à grande échelle » des interventions. En collaboration avec les responsables du programme d’application des connaissances d’Action diabète Canada, l’équipe de recherche étudiera la possibilité d’appliquer ce programme à grande échelle et cherchera de nouveaux sites destinés à sa mise en œuvre. Les résultats obtenus feront progresser la science liée à la mise en œuvre en fournissant de l’information concrète sur les étapes, les processus, les rôles et les responsabilités nécessaires pour implanter à grande échelle en Ontario, au Québec et à l’Île-du-Prince-Édouard une intervention prometteuse qui a fait ses preuves dans un environnement de recherche. La collaboration entre les chercheurs, les patients, le ministère, les fournisseurs de services de santé et les partenaires communautaires permettra de perfectionner et mettre au point de manière concertée le plan relatif à la mise en œuvre à grande échelle. Grâce à cette approche, il sera possible de répondre aux besoins de tous les intervenants qui participeront au financement, à la prestation des services ou à leur réception.

Renforcer les capacités afin de favoriser un système de santé axé sur l’apprentissage intersectoriel

Cette étude a pour but d’aider les intervenants œuvrant dans des secteurs différents à apprendre les uns des autres. La mise en œuvre de l’intervention favorise la collaboration, car elle donne aux divers fournisseurs de services la possibilité de communiquer régulièrement et de bénéficier de séances de formation commune. Grâce à cette approche, ils sont en mesure d’apprendre les uns des autres et de comprendre à quel point les autres secteurs contribuent à améliorer les soins axés sur la personne.

Diabetes Research Gets a Security Upgrade

 

The National Diabetes Repository is making great strides in transforming health outcomes for Canadians.  The National Diabetes Repository is a secure research environment in which researchers can run advanced analysis on health data-sets to study behaviour trends and how to better treat people with diabetes to prevent complications.  In a recent article by Compute Ontario, Conrad Pow, our Senior Project Manager for the National Diabetes Repository comments on the utility of the digital tool and how it can accelerate research studies using health data in diabetes.  To read more about this article and partnership with Compute Ontario please read the full article here

OSSU CMAJ Supplement RELEASED- Engaging Patients in Health Research

Message from the Ontario SPOR SUPPORT UNIT (OSSU)


OSSU is pleased to share with you a special supplement highlighting the value of patient engagement in research through 17 innovative OSSU-funded IMPACT Demonstration projects. Engaging Patients in Health Research: the Ontario Experience, published today in CMAJ (Canadian Medical Association Journal), features in-the-trenches experiences, tips and challenges from 17 IMPACT projects ranging from youth involvement in mental health services to suicide prevention, Indigenous health, children with complex medical needs and more.

The comprehensive collection of articles is a resource for researchers and others interested in this growing approach that involves patients and caregivers as partners in health and health systems research. It is also a valuable addition to the literature.

An infographic and an engaging podcast featuring interviews with researchers and patients provide excellent overviews of the content.

As a stakeholder in patient-oriented research, we thought you would be interested in this unique collection. Please feel free to share it through your networks, on social media and through other communications channels.

Vasanthi Srinivasan

 

 

CNIB Eye Van truck-trailer to be replaced for 2019 tour

 

SUDBURY—The CNIB (Canadian National Institute for the Blind) Medical Mobile Care Unit will once again serve around 4,500 patients on its annual tour of Northern Ontario. However, this will be the last time the present unit will make the trip, as a new unit will be in place for next year’s tour.

Click Here to read full story as published by Tom Sasvari on the Manitoulin Expositor

Congratulations Dr. Michelle Griever, the new Gordon F. Cheesbrough Research Chair

Diabetes Action Canada will like to congratulate Dr. Michelle Greiver on her appointment as the new Gordon F. Cheesbrough Research Chair in Family and Community Medicine at North York General Hospital (NYGH) and Director of the University of Toronto Practice-Based Research Network (UTOPIAN) at the Department of Family and Community Medicine (DFCM)

Dr. Greiver comes to the role after more than 15 years of experience with PBRNs. She was a founding member and then lead of the North Toronto Research Network (NorTReN). NorTReN was initiated under the leadership of past DFCM Chair Dr. Walter Rosser and was a precursor for UTOPIAN.  Dr. Greiver then worked with Drs. Lynn Wilson, Eva Grunfeld and David White on the initial development and successful launch of UTOPIAN.  She became Deputy Director of UTOPIAN in July 2016 and then Acting Director upon the departure of Dr. Frank Sullivan, inaugural Cheesbrough Chair and immediate past UTOPIAN Director, in April 2017.

Diabetes Action Canada is proud of you and your new endeavor.

Click here to read full article as published by the Department of  Family and Community Medicine University of Toronto.

Announcing the recipient of the Diabetes Action Canada Fellowship Awards 2018-2020

DAC Training and Mentorship Program Fellowship Awards 2018-2020


 

This year, the Diabetes Action Canada Training and Mentoring Program will be granting one Post-doctoral Fellowship Award, peer-reviewed by Diabetes Canada, of $50,000/year for a period of two years.

We are pleased to announce the successful recipient of the scholarship award for the Post-doctoral Fellowship 2018-2020:

Françoise Proust – Université de Laval, École de Nutrition

 

Congratulations Françoise and good luck with your research project!

Training and Mentoring Policies

Mentorship and Internship Procedural Plan

Application & Approval Process

  1. Information and application forms in both languages are provided on DAC website (follow-up with Cathy)
  2. Training & Mentoring Coordinator receives and screens application forms and relevant documents
  3. Training & Mentoring Coordinator adds applicants information to tracking database
  4. Training & Mentoring Goal Group Leads evaluate (using evaluation criteria/chart) and recommend to the Co-Scientific Leads
  5. Co-Scientific Leads submit the recommendations to the Steering Council (Quarterly meetings)
  6. Diabetes Action Canada Central Admin updates Training & Mentoring Coordinator on the decision of the Steering Council

Next Steps

Follow-up by Training & Mentoring Coordinator:

  • informs awarded candidates and provides additional information if needed
  • updates Mentorship/Internship tracking database

Mentorship/Internship Report reminders

  1. Training & Mentoring Coordinator monitors reminders for reports due
  2. Training & Mentoring Coordinator sends an email to candidates for reports
  3. Training & Mentoring Coordinator updates database

Award Selection Criteria

[bs_collapse id=”collapse_98de-f2a1″]
[bs_citem title=”

DAC TRAINING AND MENTORING APPLICATION REVIEW CRITERIA – MENTORSHIP PROGAM 2017-18

” id=”citem_f886-e674″ parent=”collapse_98de-f2a1″]

 Eligibility criteria:

  • The applicant must be a member of the DAC Network.
  • Early career investigators must be within three years of their university appointment and have a research program deemed to be of excellent scientific quality. An appointment start date must be included in the Candidate’s Research Program Section of the application.
  • The applicant’s research and mentorship plan must relate to diabetes and its complications.
  • The applicant must propose a mentorship plan that demonstrates capacity building in Patient-Oriented Research (e.g. establishment of new multidisciplinary and/or intersectoral collaborations within a network of patient-oriented research).
  • The applicant must have the support of 1) an internal mentor from his/her research centre, and 2) an external mentor from a different research centre recognized by CIHR. At least one of the two mentors should be a member of the DAC Network. These mentors should be actively involved in the scientific leadership of the applicant, including student co-supervision, scientific collaboration, access to specialized platforms, etc.
  • The applicant must submit a mentorship plan that has been discussed and approved by both internal and external mentors. A detailed description of the mentorship plan should be submitted for evaluation.
  • Submit a CIHR CCV (with the Detailed Contributions section) of the applicant and mentors (internal and external) to assess scientific excellence. If the mentors are outside Canada, any CV containing information similar to the CIHR CCV will be accepted.
  • A one-year budget plan of expenditures (limit $10,000), see below for eligible expenses.
  • Successful candidates agree to provide a brief report each year for 3 years to demonstrate the leverage effect of the program (i.e. new collaborations, obtaining scholarships and/or external grants).

Note: Although not a criterion, applicants from rural or less connected communities will be given priority if proposed research program deemed appropriate.The Diabetes Action Canada Network supports equity in its Mentorship program and encourages applications from qualified individuals, women or men, including Aboriginal people, persons with disabilities and members of visible minorities.

Application Evaluation Process:

  • Potential of the candidate: Quality of research training, scientific achievements, history of publication, funding and training of students;
  • Research program: Clarity of the research question and scientific justification. Potential for the creation of new knowledge, originality of assumptions and research questions, new approach, or methodologies or new application of existing methodologies;
  • Affiliation and expertise of the proposed mentors;
  • Relevance and quality of the proposed intercentre mentorship plan: Immediate or potential impact of mentorship for the early career investigator’s laboratory/research and research within the DAC Network (e.g. establishment of new multidisciplinary and/or intersectoral collaborations within a network of patient-oriented research);
  • Feasibility of the proposed budget: Relevance of the proposed use of funds.

 Scoring SystemScores out of 50

  1. QUALITY OF THE APPLICANT (TRAINING, PUBLICATIONS, ETC.) – 20 points

Applicant’s score:      /20 points

  1. QUALITY OF THE MENTORSHIP PLAN AND ALIGNMENT WITH DIABETES ACTION CANADA NETWORK OBJECTIVES – 20 points

Applicant’s score:      /20 points

  1. QUALITY OF THE MENTORS – 10 points

Applicant’s score:      /10 points

Note: Considerations and pertinence related to POR (sex and gender, etc.) will be judged by the Patient Engagement Group in the next round.


[/bs_citem]
[bs_citem title=”

DAC TRAINING AND MENTORING APPLICATION REVIEW CRITERIA – INTERNSHIP PROGAM 2017-18

” id=”citem_93fc-939e” parent=”collapse_98de-f2a1″]

 Eligibility criteria:

  • The applicant must be a doctoral student, a postdoctoral fellow, a health professional research trainee, or a research professional and member of the DAC Network by the time of tenure of the grant (not necessarily before).
  • The applicant’s supervisor must be a PI or Co-I of the DAC Network (e. before the application).
  • Only one application per year per PI or Co-I in total may be submitted for this contest.
  • Any applicant can only receive this support grant once.
  • The applicant must provide a description of relevant training and integrate it into an intercentre collaborative project (incorporating at least two recognized research centers) involving at least one researcher of the DAC Network.
  • Successful candidates agree to submit a scientific abstract for oral or poster presentation at the Annual Scientific Meeting of Diabetes Canada or other major national and international diabetes research conferences.
  • Successful candidates agree to provide a brief progress report after the one-year funding and to respond to a short questionnaire yearly for another 2 years to document impact (i.e. new collaborations, obtaining scholarships and/or external grants).

Application Evaluation Criteria and Process:

 For DAC PIs, Co-Is and collaborators:

  • Excellence in home and host laboratories: Description of performance, scientific contribution and expertise of the laboratories involved in the collaboration;
  • Relevance and quality of the proposed intercentre training: Immediate or potential impact of mentoring for the original laboratory and research within the network, according to its objectives (ex. establishment of new multidisciplinary and/or intersectoral collaborations inside the DAC Network or at an international level, knowledge transfer, patient-oriented research, standardization of methods, establishment of a platform or common resources, etc.);
  • Feasibility of the proposed budget: Relevance of the proposed use of funds.

For the student/intern/resident/professional:

  • For doctoral students, residents and postdoctoral fellows:
  1. Holding an excellent record of publication and participation/involvement in scientific activities.
  • For research professionals:
  1. Must be actively involved in activities related to the priorities of the DAC Network as in research platforms, multi-centric projects, provincial, national or international research networks.
  • Demonstrate motivation to pursue a career in research areas related to diabetes and its complications.

Note: Although not a criterion, applicants from rural or less connected communities will be given priority if proposed research project is deemed appropriate.

The Diabetes Action Canada Network supports equity in its Internship program and encourages applications from qualified individuals, women or men, including Aboriginal people, persons with disabilities and members of visible minorities.

Scoring SystemScores out of 50

  1. QUALITY OF THE APPLICANT (TRAINING, PUBLICATIONS, ETC.) – 20 points

Applicant’s score:      /20 points

  1. QUALITY OF THE TRAINING PLAN AND ALIGNMENT WITH DIABETES ACTION CANADA NETWORK OBJECTIVES – 20 points

Applicant’s score:      /20 points

  1. QUALITY OF THE MENTORS – 10 points

Applicant’s score:      /10 points

Note: Considerations and pertinence related to POR (sex and gender, etc.) will be judged by the Patient Engagement Group in the next round.


[/bs_citem]
[bs_citem title=”

Patient-Oriented Research (POR) Early Career Investigator Mentorship Award in Diabetes and its Complications 2018-2019

” id=”citem_020f-d4cd” parent=”collapse_98de-f2a1″]

Diabetes Action Canada is launching its 2018-2019 Intercentre Mentorship award for early career investigators interested in Patient-Oriented Research (POR) in diabetes and its complications. The goal of this award is to promote networking and optimal integration of early career investigators into the Diabetes Action Canada (DAC) Network and the Canadian diabetes research community. Up to two (2) annual mentorship awards will be awarded to early career investigators to work with an internal mentor and an external mentor. The internal mentor will be affiliated to the same research centre as the early career investigator. The external mentor will be affiliated with a different research centre from that of the early career investigator. At least one mentor will be a regular member of the DAC Network. Mentors who are not PI’s or Co-I’s of DAC must become DAC members before the allocation of funds.

Eligibility criteria and methods of evaluation are described below. Successful candidates will receive financial support of a maximum of $10,000 for a one-year period to support their intercentre scientific activities.

Application deadline

The deadline for submission of applications is June 29th, 2018 for funding commencing no later than September1st, 2018.

Applications submitted late, incomplete or which do not meet the eligibility criteria will not be evaluated. Proposed mentoring must be completed within the year of holding the award.

If not a DAC Network member at the time of application, successful early career investigator applicants must apply to become members of the DAC Network before allocation of award funds. Successful applicants must complete a final report at the end of their mentorship year (December 2019) and agree to subsequent annual reports for an additional two (2) years to document the impact of this mentorship experience.

Eligibility criteria for the proposed candidate:

  • The applicant must be a member of the DAC Network.
  • Early career investigators must be within three years of their university appointment and have a research program deemed to be of excellent scientific quality. An appointment start date must be included in the Candidate’s Research Program Section of the application.
  • The applicant’s research and mentorship plan must relate to diabetes and its complications.
  • The applicant must propose a mentorship plan that demonstrates capacity building in patient-oriented research (e.g. establishment of new multidisciplinary and/or intersectoral collaborations within a network of patient-oriented research).
  • The applicant must have the support of 1) an internal mentor from his/her research centre, and 2) an external mentor from a different research centre recognized by CIHR. At least one of the two mentors should be a member of the DAC Network. These mentors should be actively involved in the scientific leadership of the applicant, including student co-supervision, scientific collaboration, access to specialized platforms, etc.
  • The applicant must submit a mentorship plan that has been discussed and approved by both internal and external mentors. A detailed description of the mentorship plan should be submitted for evaluation.
  • Submit a CIHR CCV (with the Detailed Contributions section) of the applicant and mentors (internal and external) to assess scientific excellence. If the mentors are outside Canada, any CV containing information similar to the CIHR CCV will be accepted.
  • A one-year budget plan of expenditures (limit $10,000), see below for eligible expenses.
  • Successful candidates agree to provide a brief report each year for 3 years to demonstrate the leverage effect of the program (i.e. new collaborations, obtaining scholarships and/or external grants).

Note: Although not a criterion, applicants from rural or less connected communities will be given priority if proposed research program deemed appropriate.

The Diabetes Action Canada Network supports equity in its Mentorship program and encourages applications from qualified individuals, women or men, including Aboriginal people, persons with disabilities and members of visible minorities

Eligible Expenses:

Any expenses related to mentorship support for the recipient according to CIHR research grant standards. This may include:

  • transportation and accommodation costs for external mentor visits to the early career investigator’s research centre;
  • transportation and accommodation costs for the early career investigator to the external mentor’s research centre;
  • transportation, accommodation and registration at conferences/meetings for the early career investigator if at least one of the mentors is present at the same event and a meeting is on the agenda; or
  • costs related to intercentre scientific collaborations (support of early career investigators directly involved in the intercentre collaboration, supplies, technical services, etc.).


[/bs_citem]
[bs_citem title=”

Patient-Oriented Research (POR) Intercentre Trainee Internship Award in Diabetes and its Complications 2018-2019

” id=”citem_d129-44e0″ parent=”collapse_98de-f2a1″]

 

Diabetes Action Canada is launching its 2018-2019 Intercentre Internship competition for graduate students, postdoctoral fellows, and research professionals interested in Patient-Oriented Research (POR) in diabetes and its complications. The goal of this award is to promote networking and optimal integration of trainees into the Diabetes Action Canada (DAC) Network and the Canadian diabetes research community. Up to two (2) annual internships will be awarded to trainees. The DAC Network invites researchers who are PI’s or Co-I’s of the DAC Network to propose collaborative projects in the areas of diabetes and its complications and for which a trainee will complete his training in another laboratory (in another research centre). This project will involve a DAC Network PI or Co-I with one or more collaborators of another Patient-Oriented Research centre. Every collaborator must be a member of the DAC Network (or another SPOR Network) and participate in its activities.

Eligibility criteria and methods of evaluation are described below. Successful candidates will receive financial support of a maximum of $10,000 for a one-year period to allow the establishment of the trainee-based collaboration between the collaborators.

Application deadline

The deadline for submission of applications is June 29th, 2018 for funding commencing no later than September 1st, 2018.

Applications submitted late, incomplete or which do not meet the eligibility criteria will not be evaluated. Funded projects must be completed within the year of holding the award.

If not a DAC Network trainee member at the time of application, successful applicants must apply to become members of the DAC Network in order to receive the grant. Recipients must complete a final report at the end of their year of funding and agree to respond to subsequent annual short questionnaires for an additional two (2) years to document the impact of this internship experience.

Eligibility criteria:

  1. The applicant must be a doctoral student, a postdoctoral fellow, a health professional research trainee, or a research professional and member of the DAC Network by the time of tenure of the grant (not necessarily before).
  2. The applicant’s supervisor must be a PI or Co-I of the DAC Network (e. before the application).
  3. Only one application per year per PI or Co-I in total may be submitted for this contest
  4. Any applicant can only receive this support grant once.
  5. The applicant must provide a description of relevant training and integrate it into an intercentre collaborative project (incorporating at least two recognized research centres) involving at least one researcher of the DAC Network.
  6. Successful candidates agree to submit a scientific abstract for oral or poster presentation at the Annual Scientific Meeting of Diabetes Canada or other major national and international diabetes research conferences.
  7. Successful candidates agree to provide a brief progress report after the one-year funding and to respond to a short questionnaire yearly for another 2 years to document impact (i.e. new collaborations, obtaining scholarships and/or external grants).

Eligible Expenses:

Any expenses related to internship support for the recipient according to CIHR research grant standards. This may include:

  • Transport, accommodation and living expenses (if necessary depending on the distance) for the trainee(s) in the collaboration laboratory;
  • Shipping costs between the main laboratory and the collaboration laboratory(ies) in connection with the trainee’s stay;
  • Purchase of supplies necessary for the trainee’s setup in the collaboration laboratory(ies) (the purchases can be made in the host laboratory or in the main laboratory).

 Ineligible Expenses:

  • Transport, accommodation and living expenses for the trainee in his/her main laboratory; Salary for trainees or other researchers.

Application Submission Process:

  • Application form completed by the trainee or research personnel;
  • A CIHR CCV (with the Detailed Contributions section) of the trainee or research personnel.

All documents must be submitted (in PDF format) to the DAC Training and Mentoring Coordinator, Michelle Murray, Michelle.Murray@umoncton.ca.

Application Evaluation Criteria and Process:

All applications will be assessed according to the eligibility criteria of the competition and the following criteria. Successful candidates will be notified by July 13th, 2018.

For DAC PI’s, Co-I’s and collaborators:

  • Excellence in home and host laboratories: Description of performance, scientific contribution and expertise of the laboratories involved in the collaboration;
  • Relevance and quality of the proposed intercentre training: Immediate or potential impact of mentoring for the original laboratory and research within the network, according to its objectives (ex. establishment of new multidisciplinary and/or intersectoral collaborations inside the DAC Network or at an international level, knowledge transfer, patient-oriented research, standardization of methods, establishment of a platform or common resources, etc.);
  • Feasibility of the proposed budget: Relevance of the proposed use of funds.

For the student/intern/resident/professional:

  • For doctoral students, residents and postdoctoral fellows:
    • Holding an excellent record of publication and participation/involvement in scientific activities.
  • For research professionals:
    • Must be actively involved in activities related to the priorities of the DAC Network as in research platforms, multi-centric projects, provincial, national or international research networks.
  • Demonstrate motivation to pursue a career in research areas related to diabetes and its complications.

Note: Although not a criterion, applicants from rural or less connected communities will be given priority if proposed research project is deemed appropriate.

The Diabetes Action Canada Network supports equity in its Internship program and encourages applications from qualified individuals, women or men, including Aboriginal people, persons with disabilities and members of visible minorities.

Any request for additional information can be forwarded to the DAC Training and Mentoring Coordinator, Michelle Murray, Michelle.Murray@umoncton.ca.


[/bs_citem]
[/bs_collapse]

 

Diabetes Action Canada Terms of Reference for Governance Committees

CONTENTS 

[bs_collapse id=”collapse_dc4e-a604″]
[bs_citem title=”

1. Terms of Reference for the Steering Council

” id=”citem_658f-c555″ parent=”collapse_dc4e-a604″]

  • Ensure that the Vision and Mission of the SPOR Network are fulfilled through a strategic, accountable, committed leadership and management functions
  • Through the skill-based and partnership governance structure, create the highest quality oversight, communication, support and guidance for the conduct of the patient-oriented research goals using best (corporate) governance principles;
  • Develop appropriate agreement and memorandum documents articulating terms suitable for membership in the SPOR Network including specific description of participation and co-investment of resource (time, expertise, infrastructure and revenues);
  • Enable strict financial oversight using standard accounting and auditing measures;
  • Promote strategic partnership relationships with inaugural (core) and new members (academic, public and private) of the SPOR Network with sensitivity to balancing gender, age, language (French, English);
  • Incorporate local academic and clinical nodes of the Network in strategic project development, implementation and evaluation;
  • Monitor governance performance including excellence and sustainability of the leadership, management and engagement of the participating members;
  • Manage conflict of interest through appropriate processes including necessary agreements establish for all aspects of governance and research partnerships.

[/bs_citem]
[bs_citem title=”

2. Steering Council Executive

” id=”citem_375c-360e” parent=”collapse_dc4e-a604″]

  • To review and approve the agendas for the Steering Council Meetings;
  • To review strategic initiatives and partnership proposals brought forward by the Strategic Partnerships and Innovation Standing Committee;
  • To review nomination of new members or re-appointment of members to the Steering Council and its Standing Committees, as proposed by the Nomination/Governance Standing Committee;
  • To advise Co-Scientific leads and Executive Director about issues arising between meetings of the Steering Council that require executive decision;
  • To review the draft Annual Financial Report to CIHR and Network Partners, as submitted by management with oversight by the Finance/Audit Standing Committee;
  • To work closely with the Co-Scientific Leads and Executive Director on all matters related to fulfilling the objectives of Diabetes Action Canada.


[/bs_citem]
[bs_citem title=”

3. Standing Committees of the Steering Council

” id=”citem_9322-d7b5″ parent=”collapse_dc4e-a604″]

Members of the Steering Council along with other relevant leaders (e.g. Network Directors and collaborating experts) will serve on the following three Standing Committees:

  1. Strategic Partnerships and Innovation Standing Committee
  2. Nomination/Governance Standing Committee
  3. Finance/Audit Standing Committee


[/bs_citem]
[bs_citem title=”

4. Terms of Reference for the Standing Committees

” id=”citem_2abd-b60a” parent=”collapse_dc4e-a604″]

a) Strategic Partnerships and Innovation Standing Committee

  1. To develop and oversee the implementation of all the internal and external strategic partnerships for the collaborative research, KT and education projects that are undertaken by the Network Goal Groups;
  1. Responsible for advising about the ongoing strategic planning and evaluation of these activities;
  1. To receive the annual reports of each of the Goal Groups and the Scientific Advisory Panel and to advise the Steering Council;
  1. To advise about the strategic plans for support and sustainability of the Network.

b) Nomination/Governance Standing Committee

  1. To recruit and nominate members of the Steering Council including the Executive. A slate of new members will be brought forward to the Steering Council annually as necessary in their Fall Face-to-Face Meeting;
  1. The Committee Chair along with the Chair of the Steering Council and Co-Leads will be responsible for orientation of new members of the Council;
  1. Responsible for organizing and implementing the evaluation of the performance of the Steering Council as well as the annual performance of the Co-Leads (Academic);
  1. To assist in recruitment of Members of the Standing Committees of the Steering Council

c) Finance/Audit Standing Committee

  1. To develop the annual revenue/expense budget of the SPOR Network for approval by the Steering Council;
  1. To report the quarterly actual against budget to the Steering Council;
  1. To oversee the annual formal financial audit for the Network’s annual report.
  2. To recommend an auditor for the SPOR Network


[/bs_citem]
[bs_citem title=”

5. Patient-Oriented Research (POR) Program Committee

” id=”citem_a46d-7e0a” parent=”collapse_dc4e-a604″]

  • Coordinates and monitors all research, KT and education translation activities within the Network with advice from the Patient Circles
  • Ensure the work plans are executed with adherence to timelines
  • Evaluative reporting on outputs and outcomes
  • Advises the Steering Council about new Network members
  • Provides guidance and feedback on strategic directions of the Network, including changes to implementation of projects or development of new opportunities
  • Advises Goal Groups about new opportunities for acquiring new revenues and partners
  • Receives annual reports of all of the projects and evaluates progress toward target deliverables and milestones
  • Assists in preparation of the annual budget with the Executive Director and DAC Administrative team
  • Assists the management team in ensuring timely reporting of the revenues and expenses and assessing financial targets according to the planned budget throughout the year
  • Works closely with institutional fund-raising leads to leverage new resources to meet and exceed the target for matched funding

Members:

The POR Program Committee represents the core Principal Applicants and Principal Knowledge Users of Diabetes Action Canada SPOR Network and invited subject matter experts who are responsible for the implementation of all of the programs and projects constituting this research, knowledge translation and training alliance.   This meeting is held monthly and is meant to ensure continual communication, relationship-building, collaboration and synergy among our key leaders.  The POR Program Committee is an integral part of the Diabetes Action Canada governance structure and provides strategic, critical and innovative thinking in the implementation of Diabetes Action Canada programs and projects.

To see more on this committee click here
[/bs_citem]
[bs_citem title=”

6. Patient Circles

” id=”citem_0d04-7067″ parent=”collapse_dc4e-a604″]

Diabetes Action Canada Patient Circles: Overview and Terms of Reference

Goals of the Patient Circles

The goals of the Patient Circles are:

  1. to foster patient-oriented research relevant to diabetes; and
  2. to contribute to better quality research on diabetes and its related complications.

To accomplish these goals, the Patient Circles aim to:

  • Bring together diverse groups of people who bring a variety of backgrounds, expertise, ideas, types of diabetes, and personalities
  • Foster understanding across these groups
  • Create a community of people living with diabetes and their caregivers (hence referred to as Patient partners) who will be involved fully as partners of the Network
  • Build capacity for patient engagement in research on diabetes and its related complications in collaboration with the Training and Mentoring Group of the Network
  • Ensure that Patient partners are involved at every level (governance, tactical and operational) of the Network and in all phases of the research process (planning of studies, conducting the studies, disseminating the studies’ results, and implementing results of studies)
  • Foster communication among and between researchers and those whose lives are most affected by research findings, namely, patients and their family members.

We will regularly report on our progress on these points.

Responsibilities of Members of Patient Circles

  • Articulate what matters to patients, families, and communities to inform what diabetes-related research should be done and how it should be done
  • Bring knowledge and ways of knowing from other communities to diabetes research
  • Support a strong patient voice in working groups, committees and research teams
  • Identify and establish local connections to build Diabetes Action Canada’s network of Patient partners
  • Share news about Diabetes Action Canada with their communities
  • Help disseminate research findings within communities of people affected by diabetes (including, if desired, helping to organize meetings where researchers can bring research findings to communities or health professionals such as certified diabetes educators or dietitians can present best practices)
  • Solicit feedback from members of those communities of people affected by diabetes

The Patient Circles adhere to the Guiding Principles set out by the Canadian Institutes of Health Research (CIHR) in the Patient Engagement Framework. These are:

  • Inclusiveness: Patient engagement fully integrates a diversity of patient perspectives
  • Support: Adequate support and flexibility are provided to patient participation to ensure that they can contribute fully to discussions and negotiations
  • Mutual Respect: Researchers, practitioners, and patients acknowledge and value each other’s expertise and experiential knowledge
  • Co-Build: Patients, researchers, and practitioners work together from the beginning to identify problems and gaps, set priorities and work together to produce and implement solutions.

This is a living document, as the Patient Circles become more established and as Diabetes Action Canada progresses, changes may be required.

Leadership & Membership of the Patient Circles

To begin, there will be three distinct Patient Circles composed of diverse groups of people who live in Canada and who have diabetes themselves (type 1, type 2 or other types) or who are primary caregivers for persons with diabetes.  Each Circle (Collective Patient Circle, Indigenous Patient Circle, Francophone Patient Circle) will include about 12-16 members. The Collective Patient Circle will include at least two liaisons from each of the other Circles. Liaisons will help facilitate smooth communication between Circles and to help ensure that the Collective Patient Circle appropriately incorporates the voices of members of specific populations. Over time, the structures of Circles may change. For example, we initially envisioned having a separate Circle of people who immigrated to Canada as adults, but members of this Circle preferred to be integrated into either the Collective or Francophone Circle, depending on preferred language. We may also add more Circles; for example, we envision possibly adding a French-speaking Indigenous Patient Circle, a Youth Circle, and perhaps others. The Circles will be structured as follows:

Collective Patient Circle

  • 12-16 members, at least 4 who are also members of the other 2 Patient Circles
  • Persons ensuring functioning of Circle: Holly Witteman, Olivia Drescher
  • Additional support: Jon McGavock, Joyce Dogba, Marie-Claude Tremblay
  • Anticipated frequency of meetings: 8 meetings per year, 90-minute teleconferences
  • Language of meetings: English

Francophone Patient Circle

  • 12-16 members, including at least 2 who are also members of the Collective Patient Circle
  • Persons ensuring functioning of Circle: Joyce Dogba, Olivia Drescher
  • Additional support: Jon McGavock, Holly Witteman, Marie-Claude Tremblay
  • Anticipated frequency of meetings: 4 meetings per year
  • Language of meetings: French

Indigenous Patient Circle

  • 12-16 members, including at least 2 who are also members of the Collective Patient Circle
  • Ideally, this Circle will include 2-3 elders
  • Persons ensuring functioning of Circle: Alex McComber, Jon McGavock, Marie-Claude Tremblay, Pusha Sadi
  • Additional support: Holly Witteman, Joyce Dogba, Olivia Drescher
  • Anticipated frequency of meetings: 4 meetings per year
  • Language of meetings: Mostly English; Indigenous languages when possible

 Patient Circles’ representativeness

Each Patient Circle will aim to have an approximately equal representation of men and women.

Taken together, the Patient Circles will also aim to represent:

  • People of different ages, racial, ethnic, and socioeconomic backgrounds.
  • People whose lives are affected by type 1, type 2, and other types of diabetes.
  • People from different regions of Canada.
  • People who are Indigenous from nations located within Canada, settlers born in Canada or who immigrated as children, and people who immigrated to Canada as adults

SPOR Diabetes Network Patient Engagement and Indigenous Health Team Roles

Diabetes Action Canada’s Patient Engagement and Indigenous Health teams will support and coordinate activities of the Patient Circles. They will:

  • help plan the meetings;
  • organize teleconferences;
  • distribute materials and minutes to Patient partners, specifically:
    • send meeting documents by email as soon as they are available, in both Microsoft Word and pdf formats, and
    • aim to send a final package of meeting documents one week in advance of the meeting, noting documents that are duplicates of those previously sent; and
  • Provide administrative and other aid as required by members of the Patient Circle.

Communication guidelines

Our goal in all communication is to understand and be understood. To that end, we will:

  • avoid jargon and acronyms as much as possible,
  • explain specialized terms whenever it is not possible to avoid using them, and
  • Avoid tables and figures in documents to allow screen readers to more easily interpret the document.

Role of the Patient Circles

The Patient Circles are advisory and guidance bodies. They advise and guide Diabetes Action Canada on multiple levels to ensure that the network is responsive to what matters to patients.  The Patient Circles advise the Steering Committee.  The Steering Committee holds the ultimate governance responsibility for Diabetes Action Canada and has 50% patient or patient representative membership (6 members). Some of these may be members of the Patient Circles.

The Patient Circles also advise on research projects in a number of different ways. Advising on research projects includes discussing research projects at Patient Circle meetings to provide guidance to researchers to help make the research more relevant to patients. Members of Patient Circles as well as other patient members of DAC may also serve as Patient partners on research projects, bringing their expertise from their lived experience with diabetes to the research. Patients can provide expertise in many ways, including their experience of living with diabetes and, if applicable, complications; experience with the health system (care delivery), experience with specific treatments (drugs, surgeries, devices), and community needs.

Levels of Involvement & Time Commitments

All levels of participation are encouraged and welcomed in the Patient Circles. It is understood that the level of involvement and the time commitment possible will vary between members, given the diversity among the Patient Circles members’ jobs, personal commitments, wellness and illness, and other supports.  Depending on the level of involvement, the anticipated workload for most Patient partners will be 0.5-2 hours per week.

Members have the option to scale their commitment at any time: When a Patient partner decides to change his/ her level of commitment, he/ she may inform the lead(s) of the research team(s) or Patient Circle(s) and the Patient Engagement Coordinator. Sometimes during times of difficulty in a person’s life, it may be necessary for him/her to step away from his/her role on the Circle. In such cases, the Circle may “keep the person’s seat warm” so that they may return to the Circle when they are able. The Patient Circles will make sure that there is a succession plan for members for when they leave the Circle.

Learning from each other: When new Patient Circle members come on board, they will be offered a brief orientation and mentorship from another member. All Patient Circle members are strongly encouraged to participate in a free training session on Patient-Oriented Research. When a Patient Circle member leaves, the Patient Engagement team will organize a final meeting in which that member may provide any parting thoughts and advice they have to improve our work in future.

Meeting frequency:  The Collective Patient Circle will meet approximately eight (8) times per year, for 90 minutes by teleconference, online technology or other method selected by the group.  Other Patient Circles will meet approximately four (4) times per year, for 60-90 minutes by teleconference, online technology, or other method selected by the group. These meetings will take place during the time of day or evening most convenient for all participants, alternating if necessary to balance needs. Full-day, in-person meetings will take place at least once per year, budget permitting, ideally in different locations. Meeting frequency and method may be adapted according to the views of Circle members. For example, a Circle may choose to have less frequent, in-person meetings.

Term length: Patient Circle members will initially be encouraged to sit for a term of 1 year, starting from the first full meeting of Diabetes Action Canada Patient Circles, May 2017.  After the first year, we hope to maintain at least two thirds of Patient Circle members as active Circle members, with new members joining to help provide new perspectives and allow exiting members to pursue other activities, including possibly other roles within Diabetes Action Canada. Ultimately, we aim to have Patient Circle members take up 3-year terms, with one third of the members finishing their term each year. In this way, participation renewal will be staggered to ensure that there are experienced members, as well as new members on the Patient Circle at all times. Existing members will help informally mentor new members. As the Patient Circles take shape in the first two years, the Patient Engagement team will help to identify which members wish to continue their terms or step back, and will structure ongoing terms accordingly to balance the Circles.

Chairs: Chairship of meetings will be determined by each Circle. It is suggested that chair responsibilities be assumed by those who wish to assume them, sharing responsibilities as needed, with rotating chairs if desired. Meeting chairs will have support from the Patient Engagement team.

Decisions and Quorum:  As primarily advisory bodies, Patient Circles will not need to take formal votes frequently. When decisions are required, the Circles will aim for consensus, with an ethic of collaboration, cooperation, and trust, aiming always for respectful debate in which we all seek to understand and be understood. If consensus cannot be reached, those who disagree with the group’s decision may include their concerns in the final report to ensure that these are documented. Because the liaisons represent specific groups who may have particular needs, when decisions are made on the Collective Patient Circle that require a vote, liaisons will be invited to bring issues and/or proposed decisions to their Circles for further discussion prior to the Collective Patient Circle’s vote. The quorum of the Collective Patient Circle (number of members whose presence is necessary to make a binding decision) will be half of its members plus 1, with at least 1 liaison from each other Circle present.

Communication:  The Patient Circles will explore options (i.e., methods and frequency) for communication between meetings of the Patient Circles. This can take the form of social media, e-mails, newsletters etc. as deemed most appropriate and effective by the members of the Patient Circles.

 Working groups and committees: As the initiative evolves, a number of working groups or standing committees may be established which will provide more focused work. Members of the Patient Circles will be encouraged to join as many working groups as time and interest allows.

 Compensation: In recognition for their time spent and valuable expertise, members of the Patient Circles will be offered compensation in accordance with the Diabetes Action Canada Compensation Policy. Compensation will be provided for selected activities, including both meetings and preparation time for meetings.  Travel and accommodation costs will be reimbursed. Patient partners will have the option to decline to be compensated.

Opportunity for community at large to provide input to the Circles:  Members of the Patient Circles will be ambassadors and champions by liaising with other community organizations and groups. They will bring back any relevant input to the Patient Circles. Members of the Patient Circles are welcome to bring in any idea and/or suggestion from the community for discussion within the Circles.

References

This document draws from a number of other documents, including the Canadian Institutes of Health Research (CIHR) Patient Engagement Framework and the Patient Council Terms of Reference developed by the Can-SOLVE CKD SPOR Network and generously shared with other SPOR Networks.


[/bs_citem]
[bs_citem title=”

7. Project Coordinators Committee

” id=”citem_ee7c-7c89″ parent=”collapse_dc4e-a604″]

The Project Coordinators Committee provides a valuable source of information to the network. They are often the implementers of research and main connection among Goal Groups. They also report on the status of the Research programs and Research enabling programs including activities, progress, deliverables, events, etc.

The Committee comprises the Project Coordinators of the Goal Groups and the staff of DAC Administration.  The members of the Committee are:

Chair:  Tracy McQuire, Manager/Research Operations & Project Coordinator, Clinical Trials

Members:

  • Olivera Sutakovic, Project Coordinator, Diabetic Retinopathy
  • Helena Medeiros, Project Coordinator, Health Informatics
  • Pusha Sadi, Project Coordinator, Indigenous Peoples’ Health
  • Olivia Drescher, Project Coordinator, Patient Engagement
  • Michelle Murray, Project Coordinator, Training & Mentoring
  • Annie Barbeau Project Coordinator, Knowledge Translation
  • Conrad Pow, Project Coordinator, Digital Health to improve Diabetes Care
  • Amy Clare, Project Coordinator, Sex and Gender
  • Abdelrahman Zamzam, Project Coordinator, Foot Care and prevention of lower extremity Amputation.
  • Mildred Lim, Business Officer
  • Jessica Antwi, Administrative Assistant


[/bs_citem]
[bs_citem title=”

8. Health Informatics Working Committee

” id=”citem_600c-0b5e” parent=”collapse_dc4e-a604″]

The Health Informatics Working Committee is an ad-hoc committee established to develop a health technology strategy across the research programs of Diabetes Action Canada.

Members of the Health Informatics Working Committee:

Chair: Catharine Whiteside

Members:      

Michael Brent, Joe Cafazzo, Jean-Pierre Després, Neil Drummond, Jean-Francois Ethier, Shivani Goyal, Michelle Greiver, France Légaré, Gary Lewis, Tracy McQuire, Bruce Perkins, Conrad Pow,  Matthew Tenant, David Wong


[/bs_citem]
[/bs_collapse]

 

The Health Researcher’s Toolkit: Why Sex & Gender Matter

Women’s Xchange, Diabetes Action Canada’s Sex and Gender Enabling Research Program, has created an interactive and accessible toolkit comprised of 7 e-learning modules focused on the incorporation of sex and gender in research. Women’s Xchange has developed The Health Researcher’s Toolkit: Why Sex and Gender Matter to be as comprehensive as possible, addressing a variety of research methodologies. Sex and gender can be effectively integrated into all research design by asking specific gender questions on questionnaires, disaggregating data by sex or taking a mixed-methods approach – these modules provide a diverse array of strategies to optimize your research in order to become more inclusive.

The modules were reviewed by Diabetes Action Canada’s Patient Partner group and feature the stories of two Diabetes Action Canada Patient Partners. They highlight the importance of Diabetes Action Canada’s Patient Circles and how this model can be used by other researchers to engage with vulnerable groups and populations. The Health Researcher’s Toolkit: Why Sex and Gender Matter provide Diabetes Action Canada research teams with the practical knowledge they need to further enhance the quality of their work.

To access these the Health Researcher’s Toolkit please visit the Women’s Xchange website here

Announcing the Recipients of Diabetes Action Canada Awards (2018-2019)

 

DAC Training and Mentorship Program Mentorship and Internship Awards 2018-2019


This year, the Diabetes Action Canada Training and Mentoring Program, in collaboration with the Cardiometabolic Health, Diabetes and Obesity Research Network (CMDO), will fund six awards: three Mentorship Awards of $10,000 for a period of one year and three Internship Awards of $10,000 for a period of one year.

We are pleased to announce the successful recipients of the 2018-19 Patient-Oriented Research Early Career Investigator Mentorship Awards and the Patient-Oriented Research Intercentre Trainee Internship Awards and their affiliations:

 

Mentorship Awardees

1- Anne-Sophie Brazeau – School of Human Nutrition, McGill University

2- Jean-Sébastien Paquette – Département de médecine familiale et de médecine d’urgence, Faculté

de médecine, Université Laval

3- Neeru Gupta – Department of Sociology, University of New Brunswick

 

Internship Awardees

1- Aleksandra Stanimirovic – THETA Collaborative, Toronto General Research Institute, University

Health Network

2-  Dave Bergeron – Faculté de médecine et des sciences de la santé, Université de Sherbrooke et

Faculté de médecine, Université Laval

3- Delnaz Roshandel – The Hospital for Sick Children, Dalla Lana School of Public Health, University of

Toronto


Congratulations and good luck to all the Diabetes Action Canada 2018-2019 Awardees!

New Video: Insights from a Caregiver Research Partner

As posted on the Aging Community Health  Website

If you’re a researcher who wants to make the most of the contributions from caregiver partners, you’ll want to watch our latest video.

Gail juggles the demands of being a family caregiver and yet still makes time to be an Aging, Community and Health Research Unit caregiver research partner. In this short video she shares her experience and perspectives about caregiving and sheds light on what researchers really need to know when working with caregivers as research partners. Listen as she reveals what has worked well in partnering with research teams and the benefits she sees of being a caregiver research partner.

 

Click here to view this video

Click here to view our other videos

Diabetes 360: Framework for a National Diabetes Strategy

As posted on the Diabetes Canada Website


Diabetes Canada released the report “Diabetes 360˚: A Framework for a Diabetes Strategy for Canada. The report contains the recommendations of a coalition of nearly 120 experts from across Canada.

Excerpt From the Report
The report’s primary recommendation calls for $150 million in funding over seven years to support the development and implementation of a new national diabetes strategy. The report also recommends taking a new approach to stemming the diabetes epidemic based on the proven model used for HIV/AIDS and other global disease strategies with clearly defined targets and outcomes. Among the benefits the report details are that the program could prevent nearly a million diabetes cases from developing and save more than $9 billion is healthcare costs in the next seven years.

CMAJ – A home for patient-oriented research

 

CMAJ has recently announced CMAJ Open Patient-Oriented Research Collection.

This is an exciting opportunity for patient-oriented researchers as it provides a home for research studies that particularly specify how patients were engaged as part of the research team and how their contributions developed the work.  This group is guided by a steering committee composed of researchers and patients from across Canada and each article considered for the collection will be reviewed by both patient and peer reviewers.

Patient-Oriented research is still an emerging concept that takes time to accumulate an evidence base and to build enough collective knowledge to shape methodology. By creating a dedicated open-access repository for rigorous patient-oriented research, CMAJ Open hopes to provide a platform to answer questions about how best to engage patient partners and evaluate their impact on health research.  This will inform best practice and ultimately put relevant knowledge that matters into the hands of both patients and health professionals who can use it to improve health outcomes.

Already a podcast has been released by CMAJ as part of the Patient-Oriented Collection

Author guidelines for this collection are available as well as guidelines for patient peer reviewers.

If you or someone you know would be willing to review papers for the POR collection, it is a matter of clicking here to ‘Create an Account’, then adding “Patient Oriented Research” to areas of expertise when prompted.  If you are as Patient Partner also add “Patient Reviewer” under areas of expertise.

If you have any questions about eligibility and guidelines, please direct them to CMAJ at editorial-open@cmaj.ca.

 

Community Voices: Diabetes in Indigenous Populations

 

Community Voices: Diabetes in Indigenous Populations is a video project produced by the Institute of Health Economics in Alberta Canada and support by Boehringer-Ingelheim Canada.  This video aims to highlight Indigenous perspectives on health, and promote shared learning for a variety of stakeholders within the context of health, well-being, and health care in Canada.

New videos from the series will be added regularly to the Institute for Health Economics website here, and will highlight voices from Indigenous communities describing current issues of concern, and aspirations for the future.

Community Voices: Diabetes in Indigenous Populations – Part One

Description

The video above captures voices from the Assembly of First Nations Health Transformation Summit, which took place February 13-14, 2018.

A special thank you to Dr. Angela Mashford Pringle, Assistant Professor, University of Toronto, and Associate Director, Waakebiness-Bryce Institute for Indigenous Health; Carol Hopkins, Executive Director, Thunderbird Partnership Foundation; Regional Chief Isadore Day, Assembly of First Nations; and the Assembly of First Nations for supporting the development of this video.

Background

The Institute of Health Economics hosted a policy roundtable Diabetes Care and Management in Indigenous Populations in Canada in the Fall of 2017. A major theme emerging from the roundtable was the importance of community engagement and leadership in the development of effective health programming, which is a key component of several current initiatives at both local and national levels. At a national level, the Assembly of First Nations Health Transformation Agenda aims to support the development of health systems led, managed, and operated by First Nations communities, for First Nations communities. At the community level, there are several successful diabetes care and management programs, including the Kahnawake Diabetes Prevention ProjectDiabetes and My Nation, and the Indigenous Diabetes Health Circle, among many others, which were developed by communities to address self-identified priorities and needs.

Acknowledgements

This project was only possible through the generous contributions of many individuals across Canada, and their willingness to participate and share their perspectives, thoughts, and ideas with us, and to offer their comments and feedback on earlier versions. We thank them for their time, contributions, and seemingly limitless patience teaching us.

Project Sponsor

This project was completed with funding support, and in partnership with Boehringer Ingelheim (Canada) Ltd.

A Common Vision for Increasing Physical Activity and Reducing Sedentary Living in Canada: Let’s Get Moving

 

On May 31, 2018, federal, provincial and territorial (FPT) governments released A Common Vision for Increasing Physical Activity and Reducing Sedentary Living in Canada: Let’s Get Moving. This is Canada’s first ever national policy focusing on increasing physical activity and reducing sedentary living in Canada.

Led by the Public Health Agency of Canada at the federal level, the purpose of the Common Vision is to guide FPT governments and non-governmental organizations (NGOs) in addressing physical inactivity and sedentary behaviour among Canadians of all ages and abilities across the life stage. It reflects integrated approaches and solutions from across various sectors of society, as all orders of government build on existing efforts in this area, including how governments align and complement efforts with non-governmental organizations to increase physical activity and reduce sedentary behaviour in Canada.

The Common Vision was developed and designed collaboratively by FPT governments and was informed by a comprehensive, Pan-Canadian consultation and engagement process that included focused outreach on specific issues facing municipalities, Indigenous on and off-reserve communities, as well as northern, rural and remote communities.

The Common Vision aligns with, amplifies and supports the goals and objectives of existing policies, strategies and frameworks in Canada.

It was also informed by relevant Calls to Action of the Honouring the Truth, Reconciling for the Future: Summary of the Final Report of the Truth and Reconciliation Commission of Canada (2015).

On a global scale, the Common Vision aligns with and supports the World Health Organization’s Global Action Plan on Physical Activity, which was adopted at the 71st World Health Assembly on May 25, 2018 to encourage a comprehensive and coherent response for global and national action using a collaborative partnership approach.

Learn more about the Common

Vision<https://www.canada.ca/en/public-health/services/publications/healthy-living/lets-get-moving.html>.

_________________________________________________________________

Document Publication Date: 2018-06-01

Document Deletion Date: 2019-05-31

Category: 2. Headline News

Author Branch/Agency: HPCDP

Responsible Organization: Centre for Chronic Disease Prevention Approved By: Barrett Halliday/HC-SC/GC/CA

Contact: Joe Doiron/HC-SC/GC/CA

LANCEMENT DU RÉPERTOIRE NATIONAL DU DIABÈTE D’ACTION DIABÈTE CANADA

 

 


Action diabète Canada, une entité du programme de la SRAP sur les maladies chroniques des Instituts de recherche en santé du Canada, est ravi d’annoncer le lancement du Répertoire national du diabète.

Le Répertoire national du diabète, qui permettra la découverte au moyen de la recherche dans un environnement sécurisé et contrôlé, représente une avancée majeure en ce qui a trait à la surveillance et au traitement du diabète au Canada.

Les principaux éléments du Répertoire seront créés à partir de données issues de dossiers médicaux électroniques, à commencer par celles contenues dans les répertoires de soins primaires existants de trois provinces (Ontario – UTOPIAN; Alberta – NAPCReN et SAPCReN; Québec – RRSPUM). Ces sources fourniront les données de plus de 50 000 patients diabétiques. De plus, des plans sont en cours pour élargir la banque de données.

Action diabète Canada supervise l’utilisation des données par l’entremise d’un Comité de direction de la recherche. La moitié des membres du Comité de direction de la recherche sont des patients. L’équipe comprend également des médecins qui fournissent des données issues de dossiers médicaux électroniques, des chercheurs spécialisés en recherche observationnelle et clinique, et des experts en éthique de la recherche, en respect de la vie privée et en droit.

Le Répertoire national du diabète sera accessible aux chercheurs d’Action diabète Canada. L’objectif de ce projet de recherche consiste à améliorer le dépistage des complications et à faciliter la mise en œuvre d’interventions efficaces et opportunes pour, ultimement, améliorer la vie et la santé des Canadiennes et des Canadiens aux prises avec le diabète.

La sécurité et la confidentialité ont été des considérations d’une importance capitale au moment de délimiter les paramètres du Répertoire. Des pratiques rigoureuses relatives à la protection de la vie privée ont été intégrées aux fondements du Répertoire et incorporées à l’ensemble de nos politiques et procédures. Ainsi, nous pourrons permettre aux chercheurs d’accéder aux données, sans en compromettre la sécurité. Le Répertoire national du diabète est géré à partir du North York General Hospital, et le matériel informatique physique est hébergé au Centre for Advanced Computing, un établissement sécurisé de Calcul Canada situé à Kingston, en Ontario.

 

 

Processus de demande :

Les chercheurs se verront accorder un accès contrôlé à l’environnement sécurisé après avoir reçu l’autorisation du Comité de direction de la recherche. L’obtention d’une autorisation dépendra de l’harmonisation du projet avec les valeurs de base d’Action diabète Canada, de l’approbation du point de vue de l’éthique de la recherche et de la confirmation du financement. Les chercheurs pourront remplir et soumettre un formulaire de demande en ligne à https://repository.diabetesaction.staging0.com (en cours de développement) ou en écrivant à diabetes.repository@utoronto.ca.

 

Données :

 

Les données hébergées dans le Répertoire national du diabète sont anonymisées. Par ailleurs, Action diabète Canada supervise l’utilisation des données par l’entremise d’un solide comité de direction de la recherche.

Conformément aux paramètres du projet, comme stipulé dans le plan de création de l’ensemble de données, le ou la gestionnaire des données du répertoire versera une portion des données de recherche sur un poste de travail virtuel sécurisé aux fins d’analyse. Cette portion de données sera ensuite alignée avec la proposition de recherche approuvée par le Comité d’éthique de la recherche, et examinée et approuvée par le Comité de direction de la recherche.

 

Espace de travail aux fins d’analyse :

Les chercheurs auront accès à une suite de programmes statistiques. Il convient de noter que les données fournies pourront uniquement être consultées à partir du poste de travail virtuel sécurisé et ne pourront être extraites de leur environnement.

 

Éléments de données :

 

Allergies et intolérances Antécédents familiaux Procédures médicales
Indicateur de maladie Problèmes de santé Données démographiques
Diagnostic Résultats d’analyses de laboratoire Facteurs de risque
Rencontres médicales Médication Vaccins

 

D’autres éléments de données pourraient être rendus accessibles. En cas d’intérêt, nous vous invitons à soumettre une demande de mise à jour du dictionnaire de données.

Le lancement du Répertoire national du diabète d’Action diabète Canada apportera un éclairage scientifique sans précédent sur la santé des patients et les comorbidités, et permettra de mieux comprendre les mécanismes qui sous-tendent le diabète et ses complications

Vous avez des questions? N’hésitez pas à écrire à conrad.pow@nygh.on.ca ou à diabetes.repository@utoronto.ca.

LAUNCH OF THE DIABETES ACTION CANADA NATIONAL DIABETES REPOSITORY

Diabetes Action Canada, part of the Canadian Institutes of Health Research SPOR Program in Chronic Disease, is thrilled to announce the launch of the National Diabetes Repository.

The National Diabetes Repository will be a major step forward in the monitoring and treatment of diabetes in Canada by enabling discovery through research in a secure and controlled environment.

The core elements of the repository will be created with Electronic Medical Record (EMR) data starting with existing primary care repositories in three provinces (Ontario – UTOPIAN; Alberta – NAPCReN and SAPCReN; Quebec – RRSPUM).  This represents data for over 50,000 patients with diabetes. Plans are underway to expand data holdings.

Diabetes Action Canada has oversight of the use of the data through a Research Governing Committee. 50% of the Research Governing Committee members are patients; members also include physicians providing EMR data, researchers with expertise in observational and clinical research and subject matter experts in research ethics, privacy and law.

The National Diabetes Repository will be available to Diabetes Action Canada Researchers.  The aims of the research include improving appropriate screening for complications and facilitating effective and timely intervention to ultimately improve the lives and health of Canadian living with diabetes.

Privacy and Security have been paramount in scoping the requirements for the Repository.  Rigorous privacy practices have been embedded into the foundation of the Repository and have been incorporated into all our policies and procedures.  This will allow us to provide access to researchers without compromising data security.  The National Diabetes Repository is managed at North York General Hospital and the physical hardware is housed at the Centre for Advanced Computing (CAC), a secure Compute Canada facility in Kingston, Ontario.

Submission Process:

Researchers will receive controlled access to the secure environment upon receiving approval from the Research Governance Committee.  The approval will be contingent on alignment with Diabetes Action Canada core values, research ethics approval and confirmation of funding. Researchers will be able to electronically fill and submit an application through https://repository.diabetesaction.staging0.com (currently under development) or by contacting diabetes.repository@utoronto.ca

Data:

Data housed within the National Diabetes Repository are de-identified. Diabetes Action Canada has oversight of the use of the data through a robust Research Governing Committee.

Based on the project requirements, as outlined in a dataset creation plan, the Repository Data Manager will provide a cut of research data onto a secure virtual desktop for analysis.  This cut of data will be aligned with the REB approved research proposal reviewed and approved by the Research Governing Committee.

Analytic Workspace:

Researchers will have access to a suite of statistical programs.

It is important to note that the data provided will be restricted to the secure virtual desktop and cannot be removed from the environment.

Data Elements:

Allergy Intolerance Family History Medical Procedures
Disease Case Indicator Health Conditions Demographics
Diagnosis Laboratory Results Risk Factors
Encounter Medication Vaccine

Additional data elements may be available.  If interested, please request an updated data dictionary.

The launch of the Diabetes Action Canada National Diabetes Repository will enable unprecedented scientific insight into patient health, comorbidities and a deeper understanding of the mechanisms behind diabetes and its related complications.

Questions? Please contact conrad.pow@nygh.on.ca or diabetes.repository@utoronto.ca

Vaincre le diabète de type 1 : la FRDJ et les IRSC franchissent un pas de plus


Le 30 mars 2018 a eu lieu l’annonce très attendue des bénéficiaires des subventions de fonctionnement pluriannuelles pour les essais cliniques novateurs des Instituts de recherche en santé du Canada (IRSC) et de la Fondation de la recherche sur le diabète juvénile (FRDJ) visant à progressivement alléger le fardeau des gens atteints du diabète de type 1. Parmi les huit groupes de recherche qui ont soumis une demande, trois ont obtenu du financement. Ils recevront chacun un montant allant jusqu’à 3 000 000 $ sur une période de quatre ans. Les chercheurs associés d’Action diabète Canada, les Drs Gillian Booth et Rémi Rhabasa-Lhoret, comptaient parmi les bénéficiaires, tout comme le Dr Farid Mahmud de Can-SOLVE CKD (le Réseau de la SRAP sur la maladie rénale chronique). Voici une brève description de chacune des études :

La Dre Booth et son équipe proposent un essai clinique portant sur un modèle numérique novateur de prestation de soins de santé et des services de soutien connexes pour les personnes atteintes du diabète de type 1 recevant les soins habituels. Le modèle comprend des rendez-vous virtuels brefs, mais fréquents avec l’équipe de soins des participants, pour échanger et discuter des tendances de glycémie, de l’auto-prise en charge du diabète, des stratégies d’adaptation, des objectifs personnalisés et des plans d’action. Cette intervention regroupera également des cours structurés en ligne, des outils et de l’assistance. Les rendez-vous virtuels feront appel aux technologies de vidéoconférence, auxquelles il est possible d’accéder gratuitement et de manière sécurisée à partir de n’importe quel appareil personnel (ordinateur, tablette, téléphone intelligent).

 

Le Dr Rhabasa-Lhoret et son équipe proposent une étude portant sur les meilleures stratégies pour réduire les épisodes d’hypoglycémie. Le projet comprend l’élaboration d’une stratégie éducative en ligne ayant pour but d’aider les patients qui portent des dispositifs médicaux à suivre leur glycémie en temps réel afin d’optimiser les fonctionnalités de ces appareils. Les chercheurs ont également développé un forum de discussion entre pairs pour offrir aux participants du soutien social et leur fournir des stratégies personnelles visant à réduire le taux d’hypoglycémie.

 

Le Dr Farid et son équipe examinent les effets d’un groupe de médicaments appelé inhibiteurs des cotransporteurs sodium-glucose de type 2 (iSGLT2) chez les adolescents atteints du diabète de type 1. Ces médicaments ont déjà été associés à l’amélioration de la gestion de la maladie et la prévention des problèmes cardiaques ou rénaux à long terme dus à l’hyperglycémie chez des adultes aux prises avec le diabète de type 2.

Toutes ces études ont été conçues conjointement avec des patients et répondent directement aux inquiétudes des personnes qui vivent avec le diabète de type 1. Action diabète Canada est heureux de collaborer avec chacun de ces chercheurs. Alors que les synergies de recherche et de nouvelles collaborations émergent, Action diabète Canada travaille à la conception d’une plate-forme de santé numérique pour soutenir ces études. Plus précisément, un comité directeur associé au programme axé sur les objectifs en lien avec les innovations sur le diabète de type 1 sera formé et aura pour mission d’établir un cadre pour planifier et déployer un répertoire du diabète de type 1 qui contribuera à la mise en œuvre de ces essais cliniques. Le principal objectif du répertoire du diabète de type 1 est de faciliter le recrutement efficace en temps utile de participants pour les essais cliniques, tout en consolidant la communication sur les essais cliniques en cours et la façon d’y participer auprès des personnes qui vivent avec le diabète de type 1.

 

JDRF and CIHR are one-step closer to beating Type-1 Diabetes

 


On March 30th, 2018 the much anticipated awardees were announced for the CIHR/JDFR innovative clinical trials multi-year operating grant to progressively remove the burden from the lives of persons with Type-1 Diabetes (T1D).  Of the eight research groups that applied, three were funded with each receiving up to a maximum of $3,000,000 over 4 years.  Diabetes Action Canada co-investigators Dr. Gillian Booth and Dr. Remi Rhabasa-Lhoret were among the awardees, as well as Dr. Farid Mahmud from the CANSOLVE-CKD SPOR Network. Here is a brief description of each study.

Dr. Booth and her team propose a clinical trial testing a novel electronic delivery of health care and related support services to people living with T1D in addition to usual care including frequent, brief virtual visits with their diabetes care team to share and discuss blood sugar patterns, diabetes self-management, coping strategies, personalized goals and action plans.  This intervention will also have structured online educational courses, tools and supports. These virtual visits will use videoconferencing technology that can be securely accessed free of charge from any personal device (PC, tablet, smart phone),

 

Dr. Rhabasa-Lhoret and his team propose a study examining better strategies to reduce episodes of hypoglycemia.  This includes an online educational strategy to help patients wearing medical devices to monitor blood sugar levels in real time to optimize functionality of these devices.  This study has also developed a peer-to-peer discussion forum to offer social support and personal strategies to reducing hypoglycemia.

 

Dr. Farid and his team are examining the effects of a group of medications, called sodium glucose co-transporter 2 inhibitors (SGLT2i) in teens with T1D.  These medications have previous evidence of success in adults with T2D to improve diabetes control and prevent long-term kidney and heart issues due to high blood sugars.

All of these studies were co-developed with patients and directly address the concerns articulated by those living with T1D.  Diabetes Action Canada is thrilled to be collaborating with each of these investigators. As research synergies and new collaborations emerge, Diabetes Action Canada is designing a digital health platform to support these research studies.  In particular, the Innovations in Type-1 Diabetes Goal-Directed Program will be forming a Steering Committee to establish a framework for planning and implementing a T1D Registry to assist in implementation of these clinical trials.  The core purpose of the T1D Registry is to facilitate timely and effective recruitment of subjects to clinical trials, while enhancing communication with individuals living with T1D on current clinical trials and how to participate.

Élargir la portée du dépistage de la rétinopathie diabétique au Canada grâce à l’intelligence artificielle : nouvelle collaboration soutenue par Action diabète Canada, l’Université de Montréal et l’École polytechnique de Montréal


Touchant 8,5 % de la population adulte de la planète, le diabète est considéré comme une épidémie mondiale[i]. D’ici 2020, 10 % de la population canadienne vivra avec le diabète. Or, les personnes atteintes présentent un risque accru de détérioration de la vision, qui est la principale cause de cécité chez les adultes de moins de 60 ans (d’âge actif). La rétinopathie diabétique est une complication du diabète et représente 80 % des cas de cécité associée au diabète. Une détection précoce de la rétinopathie diabétique grâce à un dépistage régulier contribue efficacement à la prévention de la perte de vision attribuable au diabète, puisque les traitements nécessaires préviennent les dommages rétiniens irréversibles.

Action diabète Canada considère le dépistage de la rétinopathie diabétique comme une priorité de premier ordre. Cette mesure de prévention est partagée entre les autorités de santé et de télésanté financées par les provinces, qui mettent sur pied des programmes de dépistage de la rétinopathie diabétique visant à rejoindre les populations vulnérables et sous-desservies. Les programmes de dépistage rétinien à distance ont le potentiel d’être appliqués à grande échelle dans le contexte d’un programme de dépistage populationnel à plus grande portée. Pour y arriver, on doit tenir compte des contraintes de capacité diagnostique des ophtalmologistes canadiens. Dans cette optique, Action diabète Canada collabore désormais avec un groupe de chercheurs du Département d’ophtalmologie de l’Université de Montréal (UdeM) et avec l’École polytechnique de Montréal, en partenariat avec l’Institut des algorithmes d’apprentissage de Montréal (MILA). Le MILA rassemble des chercheurs de l’Université de Montréal dont les travaux sont axés sur l’apprentissage machine et l’analytique fondée sur l’intelligence artificielle. Grâce au financement qui leur a été accordé par Action diabète Canada et l’UdeM, ces chercheurs prévoient développer des algorithmes faisant appel à des technologies avancées pour faire la lecture des images du fond rétinien et des examens de tomographie par cohérence optique dans le but de poser un diagnostic détaillé de rétinopathie diabétique ou d’autres maladies oculaires. L’objectif fondamental du projet consiste à améliorer l’accès à des soins ophtalmologiques de qualité supérieure en diminuant le temps de lecture des images et en augmentant la productivité des cliniciens. Ensemble, Action diabète Canada et l’UdeM souhaitent explorer le rôle de l’intelligence artificielle dans l’analyse des images rétiniennes et son potentiel d’application dans les différents contextes cliniques au Canada et ailleurs. Après avoir mis au point et validé ses algorithmes, le groupe envisage de créer un consortium national qui pourrait se servir des technologies avancées pour permettre une analyse des images de la rétine et des examens de tomographie par cohérence optique de grande valeur d’un bout à l’autre du pays.

Cette collaboration de recherche a récemment fait l’objet d’un article paru dans le Journal de Québec. Nous vous invitons à en faire la lecture ici.

 

[i]  Rapport mondial sur le diabète. Organisation mondiale de la Santé. http://www.who.int/diabetes/global-report/fr/. Consulté le 25 septembre 2017.

 

 

 

 

Expanding Diabetic Retinopathy Screening in Canada using Artificial Intelligence: A new collaboration supported by Diabetes Action Canada, the University of Montreal and The Montreal Polytechnique

Diabetes is considered a global epidemic, affecting 8.5% of the worldwide adult population[i] . By 2020, 10% of the Canadian population will be living with diabetes. Those with the disease have an elevated risk of eyesight deterioration, which is the leading cause of blindness in adults under 60 years of age (working age).  Diabetic Retinopathy (DR) is a complication of diabetes and accounts for 80% of diabetic-related blindness.  Early detection of DR by regular screening effectively avoids vision loss from diabetes as necessary treatments prevent irreversible retina damage.

Diabetes Action Canada recognizes DR screening as a top priority. This prevention measure is shared amongst provincially funded telehealth and health authorities that are establishing DR screening programs to reach under-served and vulnerable populations.  Telehealth retinal screening programs have the potential to scale up as part of a broader population-based screening program. To accomplish this, diagnostic capacity constraints among Canadian ophthalmologists must be considered.  To address this, Diabetes Action Canada is now collaborating with a group of investigators at the University of Montreal (U of M), Department of Ophthalmology and the Montreal Polytechnique, who collaborate with the Montreal Institute for Learning Algorithms (MILA).  MILA is a federation of University of Montreal researchers focused on machine learning and artificial intelligence-based analytics.  With funding from Diabetes Action Canada and the U of M, they plan to develop algorithms using advanced technology to read retinal fundus photo images and optical coherence tomography (OCT) images for diagnosis of diabetic retinopathy and other eye disease. The fundamental goal is to improve access to high quality ophthalmological care by reducing image reading times and increasing clinician productivity.  Together, Diabetes Action Canada and U of M are interested in investigating the role of artificial intelligence (AI) in retinal image analytics and its potential for application in clinical contexts in Canada and beyond. Following algorithm development and validation, this group envisions creating a national consortium that could leverage advanced technology to deliver high-value retinal and OCT image analysis across Canada.

This research collaboration was recently featured in an article in Le Journal de Quebec found here

2018 – 19 Banting Legacy Educational Awards


Media Release June 3, 2018


The Sir Frederick Banting Legacy Foundation (SFBLF) is pleased to announce the winners of the
2018 Banting Legacy Educational Awards.
These awards are provided as support for students, living with Type 1 or Type 2 diabetes, to advance
their career aspirations through post-secondary education.
This program is one of many operated by SFBLF to Fight Diabetes and Preserve the Legacy of
Sir Frederick Banting, co-discoverer of insulin and Canada’s first Nobel Laureate.

2018 Banting Legacy Scholarship Winners
* Ms. Harkiran Moondi, Sandalwood Heights Secondary School, Brampton, ON, Peel DSB
* Mr. Michael Thornton, Monarch Park Collegiate Institute, Toronto, ON, Toronto DSB

2018 Banting Legacy Bursary Winners – Group 1
* Mr. Tyler Gysbers, Patrick Fogerty Catholic High School, Orillia, ON, Simcoe-Muskoka CDSB
* Ms. Kiersten Hillman, Bracebridge Muskoka Lakes SS, Bracebridge, ON, Trillium Lakelands DSB

2018 Banting Legacy Bursary Winners – Group 2
* Ms. Brittney Ellsworth, Wellington Heights SS, Mt. Forest, ON, Upper Grand DSB
* Mr. Darren Mills, John F. Ross Collegiate VI, Guelph, ON, Upper Grand DSB
* Ms. Linda Sturge, I. E. Weldon Secondary School, Lindsay, ON, Trillium Lakelands DSB
* Ms. Caitlyn Turner, Huntsville High School, Huntsville, ON, Trillium Lakelands DSB

The awards are based on consideration of academic achievement, leadership, creative contributions to
extra-curricular activities within school and community, diligent adherence to essential diabetes selfmanagement
protocols, a written essay selected from topics provided and supporting
recommendations from healthcare providers and community leaders.
The Directors of SFBLF congratulate the 2018 winners and wish all of them continued good health
and outstanding success. We are very proud to support such accomplished young women and men.
-30-
SFBLF (Alliston, Ontario, Canada)
The mission of SFBLF is to Fight Diabetes and Preserve a Legacy. The primary focus is on disease prevention
and disease self-management through increased awareness, education, clinical innovation and sustained
support with an emphasis on youth. Minimizing the transition challenges faced by youth living with diabetes
as they navigate from the paediatric to the adult healthcare system is a key priority.
Contact: David Sadleir, President: sadleir@mie.utoronto.ca

P.O. Box 137, Alliston, ON, Canada, L9R 1T9 www.bantinglegacy.ca
Charitable Registration No. 80740 6145 RR0001

NEWS RELEASE: LAUNCH OF THE DIABETES ACTION CANADA NATIONAL DIABETES REPOSITORY

Diabetes Action Canada, part of the Canadian Institutes of Health Research SPOR Program in Chronic Disease, is thrilled to announce the launch of the National Diabetes Repository.

The National Diabetes Repository will be a major step forward in the monitoring and treatment of diabetes in Canada by enabling discovery through research in a secure and controlled environment.

The core elements of the repository will be created with Electronic Medical Record (EMR) data starting with existing primary care repositories in three provinces (Ontario – UTOPIAN; Alberta – NAPCReN and SAPCReN; Quebec – RRSPUM).  This represents data for over 50,000 patients with diabetes. Plans are underway to expand data holdings.

Diabetes Action Canada has oversight of the use of the data through a Research Governing Committee. 50% of the Research Governing Committee members are patients; members also include physicians providing EMR data, researchers with expertise in observational and clinical research and subject matter experts in research ethics, privacy and law.

The National Diabetes Repository will be available to Diabetes Action Canada Researchers.  The aims of the research include improving appropriate screening for complications and facilitating effective and timely intervention to ultimately improve the lives and health of Canadian living with diabetes.

Privacy and Security have been paramount in scoping the requirements for the Repository.  Rigorous privacy practices have been embedded into the foundation of the Repository and have been incorporated into all our policies and procedures.  This will allow us to provide access to researchers without compromising data security.  The National Diabetes Repository is managed at North York General Hospital and the physical hardware is housed at the Centre for Advanced Computing (CAC), a secure Compute Canada facility in Kingston, Ontario.

Submission Process:

Researchers will receive controlled access to the secure environment upon receiving approval from the Research Governance Committee.  The approval will be contingent on alignment with Diabetes Action Canada core values, research ethics approval and confirmation of funding. Researchers will be able to electronically fill and submit an application through https://repository.diabetesaction.staging0.com (currently under development) or by contacting diabetes.repository@utoronto.ca

Data:

Data housed within the National Diabetes Repository are de-identified. Diabetes Action Canada has oversight of the use of the data through a robust Research Governing Committee.

Based on the project requirements, as outlined in a dataset creation plan, the Repository Data Manager will provide a cut of research data onto a secure virtual desktop for analysis.  This cut of data will be aligned with the REB approved research proposal reviewed and approved by the Research Governing Committee.

Analytic Workspace:

Researchers will have access to a suite of statistical programs.

It is important to note that the data provided will be restricted to the secure virtual desktop and cannot be removed from the environment.

Data Elements:

Allergy Intolerance Family History Medical Procedures
Disease Case Indicator Health Conditions Demographics
Diagnosis Laboratory Results Risk Factors
Encounter Medication Vaccine

 

Additional data elements may be available.  If interested, please request an updated data dictionary.

The launch of the Diabetes Action Canada National Diabetes Repository will enable unprecedented scientific insight into patient health, comorbidities and a deeper understanding of the mechanisms behind diabetes and its related complications.

Questions? Please contact conrad.pow@nygh.on.ca or diabetes.repository@utoronto.ca

Congratulations Michelle Greiver On Being Awarded a $2.6 Million Competitive Operating Grant

Diabetes Action Canada will like to congratulate  Dr. Michelle Greiver on being awarded a $2.6 million competitive operating grant. The grant will fund a SPIDER (Structured Process Informed by Data, Evidence and Research) approach, supporting primary care practices in optimizing care for patients with complex needs.

CLick here to read the full article published by  Canadian Health Care Technology

Recherche axée sur le patient (RAP) Mentorat des jeunes chercheurs en diabète et ses complications 2018-2019


Action diabète Canada lance son concours 2018-2019 de mentorat intercentre pour les jeunes chercheurs qui s’intéressent à la recherche axée sur le patient (RAP) dans le domaine du diabète et de ses complications. L’objectif de ce concours est de promouvoir le réseautage et l’intégration optimale des jeunes chercheurs au sein du réseau Action diabète Canada (ADC) et la communauté canadienne de recherche sur le diabète. Jusqu’à deux (2) bourses annuelles de seront attribuées aux jeunes chercheurs afin de travailler avec un mentor interne et un mentor externe. Le mentor interne sera affilié au même centre de recherche que le jeune chercheur. Le mentor externe sera affilié à un autre centre de recherche. Au moins un mentor sera membre régulier du réseau ADC. Les mentors qui ne sont pas des chercheurs principaux ou des co-chercheurs d’ACD doivent devenir membres d’ADC avant l’allocation des fonds.

 

Vous trouverez ci-joints les critères d’éligibilité et le processus d’évaluation ainsi que le formulaire de demande à compléter. Les candidats retenus recevront un soutien financier d’un maximum de 10 000 $ pour une période d’un an afin d’appuyer leurs activités scientifiques intercentres.

RAP Mentorat des jeunes chercheurs 2018-19

Formulaire de demande_RAP Mentorat des jeunes chercheurs 2018-19

Bonne chance à tous!


 

Patient-Oriented Research (POR) Early Career Investigator Mentorship Award in Diabetes and its Complications 2018-2019


Diabetes Action Canada is launching its 2018-2019 Intercentre Mentorship award for early career investigators interested in Patient-Oriented Research (POR) in diabetes and its complications. The goal of this award is to promote networking and optimal integration of early career investigators into the Diabetes Action Canada (DAC) Network and the Canadian diabetes research community. Up to two (2) annual mentorship awards will be awarded to early career investigators to work with an internal mentor and an external mentor. The internal mentor will be affiliated to the same research centre as the early career investigator. The external mentor will be affiliated with a different research centre from that of the early career investigator. At least one mentor will be a regular member of the DAC Network. Mentors who are not PI’s or Co-I’s of the DAC must become DAC members before the allocation of funds.

 

Please find attached the eligibility criteria and methods of evaluation and also the application form to complete. Successful candidates will receive financial support of a maximum of $10,000 for a one-year period to support their intercentre scientific activities.

Application form_POR Early Career Investigator Mentorship 2018-19

POR Early Career Investigator Mentorship 2018-19 (2)

Best of luck to all!